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naphtho[2,3-h]chromene-4,7,12-trione (1), a pyranoanthraquinone isolated from  
 
Streptomyces violaceus P950-4, showed a potent antibacterial and cytotoxic  
 
activity. A model synthesis for analogs 2-(1,2-dihydroxy-1-(oxiran-2-yl)ethyl)-4H- 
 
chromen-4-one (2) and2-(1-hydroxy-1-(oxiran-2-yl)ethyl)-1H-naphtho[2,3- 
 
h]chromene-4,7,12-trione (3) was developed by Dr. David White and Dr. Sarah  
 
Headrick. A new analog, 2-(1,2-dihydroxy-1-(oxiran-2-yl)ethyl)-1H-naphtho[2,3- 
 
h]chromene-4,7,12-trione (4), was designed to be structurally more similar to  
 
hydramycin with –CH2OH functionality on the pyranone ring and anthraquinone  
 
skeleton. Therefore, it is expected to have greater anticancer activity than either 
 
analogs 2 or 3. This dissertation will cover developments, challenges and  
 
solutions in the total synthesis of the analog 4.  
 
  Both eukaryotic and prokaryotic cell surfaces present a complex set of  
 
glycoconjugates. Glycoconjugates contain carbohydrates covalently linked to  
 
another building block of nature, such as an amino acid (peptide) or a lipid. Since  
 
most glycans, which are  complex arrays of covalently attached sugar chains, are  
 
on the outer surface of cellular and secreted macromolecules, they are in a  
 
position to modulate or mediate a wide variety of events in cell–cell, cell–matrix,  
 
cell–surface, cell–virus and cell–molecule interactions. These interactions  
 
mediate cell adhesion, cell motility, and cell–cell communication and recognition  
 




“tool set”, that will facilitate a modular approach to glycoarrays. The development  
 
consists of a derivatization of thiol-terminated mannose and galactose that will  
 
mimic the glycans on the cell surfaces, creation of nano-patterned microarray  
 
surfaces for the introduction of carbohydrates, and examination of the arrays by  
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Anthraquinone, a polycyclic aromatic hydrocarbon containing two  
 
opposite carbonyl groups at position 9 and 10 (Figure 1), is a yellow or light  
 
gray to gray-green crystal/powder. It is the most important quinine derivative of  
 
anthracene (Figure 2). In nature, it occurs in plants (aloe, cascara sagrada,  
 
senna, and rhubarb), fungi, lichens, and insects. It is commercially produced in  
 
several ways including the oxidation of anthracene with chromic acid (Scheme  
 
1), the condensation of benzene and phthalic anhydride in the presence of  
 

















    
 
 

























































Anthraquinone is the parent substance of a large class of dyes and  
 
pigments. One of the oldest mordant dyes, alizarin (Figure 3), is the  
 
anthraquinone derivative. Anthraquinone is a starting material for the production  
 
of coloring compounds, antioxidants, and polymerization inhibitors. Its derivatives  
 
are widely used as intermediates for dyes, pigments, photographic chemicals,  
 
and paints. 1-(Methylamino)anthraquinone is used as a dye and dye intermediate  
 



































Mitoxantrone (Figure 5), a simple anthraquinone derivative, is an 
 
antineoplastic agent used in the treatment of certain types of cancer, mostly  
 





B. Pyranoanthraquinones and Antitumor Activity 
 
 
One of the growing families of anthraquinones is the pyranoanthraquinone  
 
family. Some of the family members have been reported to show important  
 
properties such as antitumor and antibiotic activities. They are also referred as  
 



































pyranoanthraquinone family members are thought to be biosynthesized from a  
 
nonaketide having an appropriate starting unit. For example, in the biosynthesis  
 
of espicufolin, 2-methylbutanoyl and acetyl groups are used as the starting unit,  
 


































Pluramycins are antitumor antibiotic groups of anthraquinones with a 
 
pyranoanthraquinone core structure and they have one or more C-glycosidic  
 
substituents.3 There are a large number of compounds in this family that have  
 
either been studied and are in the process of being studied for their antibiotic and  
 
anticancer activity on studies. Some examples are Saptomycin H, Ankinomycin,  
 


























































































Another example of a pyranoanthraquinone is hydramycin (Figure 11). It  
 
has antitumor antibiotic activity and was isolated from the fermentation broth of  
 
Streptomyces violaceus P950-4 in 1991 by Bristol–Myers Squibb Research  
 
Institute in Japan.8 Vital to the molecule, and probably related to the activity  
 
associated with the compound, is an epoxide ring located as part of the  
 
substituent on the pyranone ring. 
 
 Hydramycin is most closely related in structure to kapurimycin A3 as  
 
shown in Figure 12. It was isolated from Streptomyces sp. DO-115 and was  
 
found to exhibit cytotoxic activity. Its epoxide ring has been suggested to alkylate  
 
the guanine residue of DNA.9 Detailed chemistry of kapurimycin-induced DNA  
 
cleavage with a self-complementary deoxyteranucleotide d(CGCG)2 was  
 
reported.10 The reaction mixture containing kapurimycin A3 and d(CGCG)2 in  
 
neutral pH was incubated at 0 °C. Figure 13 shows the A and B products that  
 



































































































Similarly, B produced two degraded products, C and E. The similarities between  
 
hydramycin and kapurimycin A3 reveal the possibility that the anticancer activity  
 
of hydramycin may also result from the result of this kind of interaction. 
 
Hydramycin was analyzed in some tumor cell lines. Inhibition of murine  
 
and human tumor cell growth, and in vivo cytotoxicities against B16-F10 (murine  
 
melanoma), Moser (human colon carcinoma) and HCT-116 (human colon  
 
carcinoma) were determined. Mitomycin C, a very old and established  
 
chemotherapy drug, was used as a reference. The cytotoxicity of hydramycin  
 
was found to be 300–600 times more potent than mitomycin C in terms IC50  
 
against the above-mentioned cell lines.8 
 
Its high anticancer activity mandated that a total synthesis of hydramycin  
 
be considered. Owing to the peculiar substitution pattern on the anthraquinone  
 
system, hydramycin itself is not easy to synthesize. The problem has been  
 
approached by making simpler analogs. A pair of separable diastereomers with a  
 
methyl group on the pyranone ring 2 (Figure 14) had already been synthesized  
 
and shown to be quite active. Diastereomer 2A seems more active than  
 
diastereomer 2B. While the absolute stereochemistries are unknown, one would  
 
assume that the chirality of the more active diastereomer would match that of the  
 
hydramycin (1). Their GI50’s are mostly in the 10-8 range against some cancers  
 


















Table 1. Antitumor activities of hydramycin 1 (NSC: 648910), diastereomer 2A 
 
(NSC: 731341) and diastereomer 2B (NSC: 731342).a11 
 
 Lungb Colonc Melanomad Breaste Prostatef 
Hydramycin 1.00E-10 <1.00E-10 <1.00E-10 <1.00E-10 <1.00E-10 
Diast. 2A 5.75E-08 4.62E-08 <1.00E-08 9.33E-08 3.15E-08 
Diast. 2B 3.96E-07 2.75E-07 1.09E-08 2.60E-07 1.19E-07 
a NCI protocol.11 
b Non-small cell lung A549/ATCC 
c Colon HCT-15 
d Melanoma LOX IMVI 
e Breast NCI/ ADR-RES 
 
 
Two other structurally abbreviated derivatives of hydramycin have been  
 
made 3 (Figure 15), but these are not active. This may be due to the lack of the  
 
anthraquinone skeleton in the structure. 
 
Herein I present the synthesis of a new analog 4 as shown in Figure 16.  
 
This analog is designed to be structurally more like hydramycin with the  
 
exocyclic –CH2OH group on the pyranone ring. It is thus expected to have  
 

















































II. STATEMENT OF THE PROBLEM 
 
 
A. Retrosynthetic Analysis and Synthetic challenges 
 
 
In the previous work towards the total synthesis of the hydramycin  
 
analogs two challenges were reported. The first challenge involved  
 
the synthetic strategy for the synthesis of the anthraquinone moiety which  
 
required a good approach to incorporate this system into the analogs. The  
 
second challenge was to determine the most efficient route to the pyran system.  
 
Retrosynthetic analysis with two strategies was already shown by Dr. Sarah  
 
Headrick and Dr. David White in their work towards the total synthesis of the first  
 
two analogs (Scheme 5). One pathway is the coupling of an enolate ion in the  
 
anthraquinone system with the appropriate aldehyde, followed by ring closure.  
 
The enolate, through aldol chemistry with an appropriate aldehyde, could  
 
generate an α,β-unsaturated system in the pyranone ring (Scheme 6). A decision  
 
on whether to install the functionality on the side chain before the condensation  
 
or add the functionality afterwards was needed. If the aldehyde were to be  
 
condensed with the aromatic enolate, followed by cyclization, then the  
 




The other pathway is the coupling between the aldehyde in the  
 































































the coupled product, pyranone ring formation could be achieved by ring closure.  
 
The required ethynyl ketone could be generated through the coupling of the  
 
aldehyde with an organometallic derivative of the alkyne and oxidation of the  
 
resulting alcohol. The resulting keto compound could be cyclized into the  
 
required pyranone compound. Therefore, this strategy proved to be more  
 
successful, and the methodology could be employed using an anthraquinone  
 

















Scheme 7. Pathway to the pyranone through alkynyl coupling 
 
 
An additional synthetic challenge involved in the synthesis of 4 (Figure 16)  
 
was the formation of the epoxide in the presence of the appropriate protecting  
 
group of the primary alcohol in the pyranone ring and removal of the protecting  
 


























Scheme 8. Deprotection without epoxide ring opening 
 
 16
B. Dissertation Summary 
 
The new analog 4 (Figure 16) is closer in structure to hydramycin (1) and due to  
 
the presence of the –CH2OH group, it has the potential of having greater  
 
anticancer activity with several cancer cell lines than either 2 or 3. This  
 
dissertation will cover challenges and solutions towards the synthesis of the  
 
analog, and will give appropriate intermediates and strategies for the future work  
 






































A. Model Synthesis 
 
 
1. Model synthesis of 3 
 
Scheme 9 shows a successful model synthesis developed by Sarah  
 
Headrick that gave compound 3. This route involves the coupling of alkyne 5  
 
and aldehyde 6 as outlined on the retrosynthetic analysis. First the alkyne 5 was  
 
reacted with two equivalents of MeMgBr for 3 h, and then MOM-protected  
 
aldehyde 6 was added.12 The secondary alcohol 7 that resulted from the coupling  
 
of the aldehyde and alkyne was oxidized to ketone 8 with MnO2.13 The required  
 
acidity was provided by 1 M H2SO4 for deprotection of the MOM and TBS groups  
 
to give the expected phenol with primary alcohol 9. The ring-closure reaction was  
 
accomplished by subjecting 9 to KF and 18-crown-6 providing 10. Finally, m- 
 





































































2. Model synthesis of intermediate 5 
 
The synthesis of the alkyne intermediate was developed by David White  
 
and Sarah Headrick and is shown in Scheme 10. Thus the sodium salt of  
 
chloroacetic acid reacted with sodium benzyloxide in benzyl alcohol yielding 11.14  
 
The acid 11 was initially converted to its Weinreb amide 12 with 1,1’- 
 
carbonyldiimidazole and N,O-dimethylhdroxylamine hydrochloride in THF.15 The  
 
benzyl group of the amide was deprotected via hydrogenation with a Pd/C  
 
catalyst in ethanol to give alcohol 13. Amide 14 resulted from reprotection with  
 
TBSCl, imidazole and DMAP in DMF. The TBS protecting group was chosen  
 
because it could be deprotected easily in a later step in the synthesis of 3 as  
 
shown in Scheme 9.  The Weinreb amide was reacted with lithium  
 
trimethylsilylacetylide to yield acetylinic ketone 15.16 The ketone was  
 
subsequently obtained by the attack of vinylmagnesium bromide in THF to give  
 
the tertiary alcohol 16,17 and removal of trimethylsilyl group was accomplished  
 




















































































B. Synthesis of Intermediates and Coupling Attempts 
 
 




Once the model compound synthesis had proven that the MOM protecting  
 
group could be deprotected in the presence of the functional groups provided by  
 
the alkyne, synthesis toward the MOM-protected anthraquinone aldehyde 22  
 
began (Scheme 11). For this synthesis, 1-hydroxyanthraquinone was used as a  
 
commercially available starting material. Reaction of the OH group with allyl  
 
bromide in the presence of K2CO3 in DMF gave allyl ether 18.19 Next, a reductive  
 
Claisen rearrangement was carried out with Na2S2O4 in a 1:1 DMF:H2O to yield  
 
19.20 The MOM protection could be achieved with Hünig’s base and chloromethyl  
 
methyl ether, and finally isomerization to the propenyl compound 21 resulted  
 
from the reaction of compound 20 with bis(acetonitrile)dichloropalladium(II).21  
 







































































2. First attempt toward the synthesis of the analog using the coupling  
 
of aldehyde 22 and alkyne 5. 
 
 
A protecting group was needed, one that could withstand both basic and  
 
oxidative reactions, but could be removed relatively easily with mild acids. The  
 
MOM group was found to be consistent with these demands. The reactions were  
 
run on the model compound 3. 
 
The coupling reaction between the alkyne 5 and aldehyde 22 was next  
 
attempted22 (Scheme 12); however, the reaction provided numerous  
 
compounds. This result may be due to the bulk of the MOM protecting  
 






































 Precedent was found in the literature23 that indicated that the protection of  
 
the 1-hydroxyl group on the anthraquinone could be a steric hindrance in a  
 
reaction of organometallic reagents with a carbonyl group attached to the 2-  
 
position of the anthraquinone as in 22. As a way around this problem, two  
 
equivalents of the attacking species could be used on a non-protected  
 
intermediate, one to deprotonate the hydroxyl group and one to nucleophilically  
 
attack the carbonyl group. Therefore, aldehyde 24, which had been generated for  
 
use as an intermediate (Scheme 13), was targeted. Thus unprotected phenol 19,  
 
which resulted from the reductive Claisen rearrangement as described earlier,  
 
was isomerized and subjected to ozonolysis to give the aldehyde 24. Attempted  
 
coupling of the alkyne and the aldehyde is shown in Scheme 14; however, the  
 



























































































Scheme 15. Synthesis of Weinreb amide 
 
 
As shown in Scheme 15, the Weinreb amide 26 was prepared by  
 
oxidation of aldehyde 24 with hydrogen peroxide and formic acid,24 followed by  
 
reaction with 1,1’-carbonyldiimidazole and N,O-dimethylhydroxylamine  
 
hydrochloride in THF. Its formation was proved by 1H NMR spectroscopy that  
 
showed singlets at 4.20 ppm and 4.63 ppm corresponding to the Me- and –OMe  
 
protons, respectively. The Weinreb amide 26 is expected to be more reactive  
 
than aldehyde 24. Addition of a nucleophile to an N-methoxy-N-methylamide  
 

























The general reaction works well with alkyllithiums and Grignard reagents at low  
 
temperatures.25 The chemistry was applied to the attempted coupling of the  
 
Weinreb amide with the alkyne as shown in Scheme 16. However, the reaction  
 































 Several attempts to couple alkyne 5 with aldehydes and amides failed.  
 
Synthesis of a new alkyne 29 with a different protecting group began from the  
 
Weinreb amide 12 that was used in the previous alkyne synthesis (Scheme  
 
17). As described earlier, the amide was reacted with lithium  
 
trimethlysilylacetylide, and acetyleinic ketone 27 was produced. Attack on the  
 
ketone by vinylmagnesium bromide yielded tertiary alcohol 28, and treatment  
 
with K2CO3 in MeOH provided deprotected alkyne 29 with the propargyl proton at  
 








































































alkyne 29 and methoxymethyl-protected aldehyde 22 (Scheme 18) was carried  
 
out, but gave 30 with low yield (20%). 
 
 
6. Final attempt coupling 
 
 
Another attempt to improve coupling was made by running the coupling  
 
reaction without the MOM protecting group on the anthraquinone. The final  
 
attempt in coupling is the benzyl-protected alkyne 29 and the aldehyde 24 with a  
 
1-hydroxy group on the anthraquinone system (Scheme 19). Two equivalents of  
 
the alkyne were used, one to form a Li+ salt from the hydroxyl group and one to  
 
attack the carbonyl group. The reaction resulted in greater yield (53%) than the  
 
coupling of the same alkyne with the MOM-protected aldehyde. The 1H NMR  
 
































C. Synthesis directed toward the final Hydramycin Analog 
 
 
1. First attempt 
 
 Once the coupling reaction was successfully developed, the next step was  
 
to form the pyranone ring as shown in Scheme 20. Oxidation of secondary  
 
alcohol 31 was again achieved via MnO2 to give ketone 32. Disappearance of the  
 













































Scheme 20. First attempted synthesis of the hydramycin analog 4 
 
 31
spectrum corresponding to the new carbonyl carbon proved the formation of 32.  
 
In an effort to avoid using the expensive KF and 18-crown-6 to effect ring closure  
 
to 33, an alternative reagent was sought. A report in the literature shows that  
 
when a refluxing suspension of potassium carbonate in acetone was used to  
 
effect the cyclization on a similar system, products of both five-membered and  
 
six-membered ring closure were isolated (Figure 18), though the latter was  
 
decisively preferred.26 When this reaction was applied to 32, the chromenone 33  
 
was obtained, and 1H NMR analysis showed a singlet at 6.81 ppm corresponding  
 
to the unsaturated proton on the pyran ring. Since debenzylation using  
 
hydrogenolysis with H2 and Pd/C would also reduce the double bond present in  
 
the chromenone ring, the alternative Hanessian debenzylation method was  
 
used.27 In this method, phenylthiotrimethyl silane in combination with zinc iodide  
 
and tetra-n-butylammonium iodide effects cleavage of methyl and benzyl ethers  
 
under mild conditions. A mechanistic study showed the large difference in bond  
 
energies between S–Si (~70 kcal/mol), and O–Si (~108 kcal/mol) and therefore  
 





























also showed that the inclusion of n-butylammonium iodide greatly enhanced the  
 
cleavage process. However, even though the literature report had supported the  
 
debenzylation in the presence of a double bond,28 the reaction did not work. 
 
 
2. Second attempt 
 
 The next attempt was to synthesize the hydramycin analog using a 1,2-  
 
diol protecting group that resulted in the alkyne 37 as shown in Scheme 21. The  
 
synthesis of the alkyne initiated with the Weinreb amide 13 containing the free  
 
hydroxyl moiety. Coupling of trimethylsilylacetylide and the amide was run as  
 
described earlier to give ketone 34. Two equivalents of the reagent were used,  
 
one to form a Li+ complex with the free hydroxyl group, and the other to attack at  
 





























35 36 37  
 
 






bromide resulted in the expected tertiary alcohol product 35. Removal of the  
 
trimethylsilyl group provided deprotected alkyne 36. The 1,2-diol alkyne was  
 
treated with 2-methoxypropene in the presence of pyridinium p-toluenesulfonate 
 
(PPTS) in acetone to give the acetonide 37,29 with methyl groups appearing at  
 
1.54 and 1.55 ppm in the 1H NMR spectrum. The use of PPTS for acid-catalyzed  
 
reactions has been quite successful and is particularly useful when TsOH is too  
 
acidic for the acid-sensitive functionality in a given substrate. Acetonide was  
 




 Once again, the alkyne was coupled with aldehyde 24 as described  
 
previously (Scheme 22). The alcohol 38 that resulted from the coupling was  
 
oxidized with MnO2. Cyclization of 39 resulted in 40. For preparing acid- 
 
sensitive epoxides (benzyloxiranes, allyloxiranes), the pH of the reaction medium  
 
must be controlled using NaHCO3 (as either the solid or aqueous solution),30,31  
 
Na2HPO4, or by using the m-CPBA–-KF reagent.32 Epoxidation of the vinyl group  
 






















































































3. Third attempt with different epoxidation methods 
 
 The next approach was to first remove the benzyl group from chromenone  
 
33 using anhydrous FeCl3 in CH2Cl2. Alcohol 41 was obtained in excellent yield  
 
(Scheme 23). The 1H NMR spectrum showed the disappearance of a multiplet at  
 
~7.05 ppm and a doublet at ~7.12 ppm corresponding to the protons in the  
 





















Scheme 23. Debenzylation using iron(III) chloride 
 
 
Several attempts were carried out for the epoxidation of 41 (Scheme 21).  
 
m-CPBA epoxidation in disodium phosphate buffer failed. The next attempt used  
 
tert-butylhydroperoxide (t-BuOOH, TBHP). This reagent is widely used as an  
 
epoxidizing agent and is considered superior to hydrogen peroxide for  
 
epoxidations because it is soluble in hydrocarbon solvents. Epoxidations of  
 
simple alkenes can be carried out using TBHP with either vanadium or  
 
molybdenum catalyst; however, reaction of 41 with VO acetylacetonate33 and t- 
 




(DDO). It is a powerful oxidant that has been particularly valuable for preparation  
 
of highly reactive products, since it can be employed under neutral,  
 
non-nucleophilic conditions which facilitate the isolation of such species.  
 
Whereas DDO performs general conversions similar to the more classical  
 
reagents like m-CPBA, it generates only an innocuous molecule of acetone as a  
 
byproduct. This is to be contrasted with peroxyacids whose acidic side-products  
 
can induce rearrangements and nucleophilic attack on products, for example, the  
 
ring opening of epoxides. Preparation of the dioxirane is shown in Scheme 25.  
 
The procedure involves the portionwise addition of oxone to a stirred solution of  
 
sodium bicarbonate in a mixture of acetone and water at 10 °C.34 The DDO  
 
generated was immediately reacted with chromenone 41 but the desired  
 
products did not form. There was difficulty in dissolving 41, in the reported  
 
solvents in Scheme 24, such as dichloromethane and acetone, and thus several  
 
































































4. Fourth attempt 
 
 
 The partial insolubility of 41 made it necessary to run the epoxidation of  
 
soluble benzyl-protected chromenone 33 using m-CPBA in basic media  
 






















Scheme 26. Epoxidation in Buffered Media 
 
 
that in the epoxidation of simple alkenes, due to the electron-releasing effect of  
 
alkyl groups, the reactivity rates are tetra- and trisubstituted alkenes >  
 
disubstituted alkenes > monosubstituted alkenes.35 Alkenes having low reactivity  
 
can be epoxidized using m-CPBA at high temperatures and by increasing  
 
the reaction time.36,37 The presence of basic media in the above reaction can  
 
also inhibit the epoxidation of the terminal alkene in 33. The epoxidation reaction  
 
was again run without disodium phosphate, and this time it gave a pair of  
 
separable diastereomers 42 in very good yield (Scheme 27). NMR elucidation  
 





































for the epoxide protons proves the diastereomeric nature of the product.  
 
A literature report shows a method developed to efficiently and selectively  
 
deprotect of both benzyl and benzylidene groups for protection of monohydroxyl  
 
and dihydroxyl groups respectively, using K-t-BuNH2, t-BuOH and 18-crown-6.38  
 
Even though the mechanism for this reaction was not reported, the study showed  
 
that deprotection has been run in the presence of an epoxide moiety. Therefore,  
 
the above reaction was run on the diastereomeric epoxides 42; however the  
 




5. Final attempt  
 
 Since the synthetic problems were largely limited to the selective removal  
 
of the protecting group of the primary alcohol in the chromenone in the presence  
 
 40
of an epoxide, silyl groups were again chosen, as they could be deprotected with  
 
weak bases. A synthesis directed toward the final analog was initiated with  
 
protection reaction of alcohol 41 using tert-butlydimethylsilyl chloride (TBSCl) as  
 













































earlier gave separable diastereomers 44. Figure 19 shows the HPLC traces for  
 
the diastereomers. The removal of the silyl group in each was carried out using  
 
tetra-n-butylammonium fluoride (TBAF) to provide diastereomers of the  
 
hydramycin analog 4. Problems were then encountered in the final reaction, as  
 













Figure 19. HPLC for the TBS protected diastereomers 
 
 42
chromatography (TLC) of each diastereomer. Both were run in 2:1 EtOAc– 
 
petroleum ether. The decomposed products were observed 24 h after  
 
purification. First, it was assumed that the epoxides were opening and closing,  
 
and, therefore, an exchange of stereochemistry was taking place; however,  
 
retention factor (Rf) measurements disproved that assumption. Careful  
 
spectroscopic analysis was then performed for diastereomer B, since it showed  
 
100% decomposition. ESIMS analysis (Figure 21) and 1D and 2D NMR analysis  
 
(Appendix A and Table 2) showed the presence of a chloro group. HRESIMS  
 
calculated for C21H15ClO7 is m/z 414.1 (100%) and 416.0 (32%); calculated [M +  
 
Na]+ m/z 437.0 (100%) and 439.0 (36 %) and was found to be 436.8 (100%) and  
 














































H (ppm) C (ppm) H (ppm) C (ppm) 
H-1 3.66, 3.99 C-1 45.53 H-2 4.36 C-1 45.53 
H-2 4.36 C-2 74.41 H-1 3.66, 3.99 C-2 74.41 
H-4 3.97, 4.28 C-4 65.03 H-2 4.36 C-3 82.04 








reaction used dichloromethane (CH2Cl2) as the extracting solvent. Studies have  
 
shown that CH2Cl2 and CHCl3 undergo a halogen exchange reaction with a  
 
similar system as TBAF, tetramethylammonium fluoride.39 The reaction with  
 
CH2Cl2 showed CH2FCl as the main product, and the reaction with CHCl3 all  
 
three possible exchange products, CHCl2F, CHClF2, and CHF3 in a molar ratio of  
 
about 2:3:1 were observed. Therefore, a chlorine atom in CH2Cl2 was replaced  
 
by the fluoride ion from TBAF during the extractive workup to give CH2ClF and  
 
tetra-n-butylammonium chloride, the latter serving as a source of chloride ion  
 
(Cl-) to ring open the epoxide to give 45 (Figure 22). This problem was solved by  
 




D. Attempted X-ray Studies 
 
 Once the diastereomers were synthesized, an X-ray study was attempted  
 
to establish both relative and absolute stereochemistry for the diastereomeric  
 
products. This study would provide answers to the stereochemistry of each  
 

















hydramycin (1). The diastereomers are insoluble in any organic solvents except  
 
for DMSO and DMF. TBS-protected diastereomers 44 are oily, and, therefore, it  
 
was impossible to crystallize them. A 4-bromobenzoyl ester derivative was  
 
chosen for this study. The idea was that a polar ester group enhances  
 
crystallization and provides a heavy atom to facilitate single-crystal X-ray  
 
determinations. Synthesis of these diastereomers began with protection reaction  
 
of the free primary alcohol 41 with 4-bromobenzoyl chloride to give 46 (Scheme  
 












































corresponding to aromatic protons in the protecting group. Epoxidation gave  
 
separable solid diastereomers 47A and 47B in good yield. After several efforts  
 
and attempts, 47B crystallized; however, the crystals formed on repeated  
 






E. Stereochemistry Determination with 1D and 2D NMR Spectroscopy 
 
 Stereochemistry of the TBS protected diastereomers 44 was then studied  
 
using COSY and NOESY and J  values. Tables 3 and 4 show correlations and J  
 
values for the diastereomers 44A and 44B, respectively. Compound 44A has  
 
a Rf value of 0.35 (3:1 petroleum ether–EtOAc) and compound 44B has a Rf  
 
value of 0.34 (3:1 petroleum ether–EtOAc). NOE correlations between H-2 and  
 
methylene H’s (H-4) were evident from the NOESY studies. Diastereomer 44B  
 
showed correlations between the above-mentioned protons, and this implies that  
 
the stereochemistry at C-2, C-4 are S,S and R,R. However, no NOE correlation  
 
was seen between H-2 and H-4 in diastereomer 44A; thus, the stereochemistry  
 
at C-2, C-4 are S,R and R,S. Refer to structures shown in Figure 23 and 3-D  
 






























H (ppm) H (ppm) H (ppm) H (ppm)  
H-1 2.75 H-1 2.98 H-1 2.75 H-1 2.98 H-2 3 .72, H-1 2.98: 4.06 Hz 
H-2 3.72 H-1 2.75 H-4 4.16 H-4 4.49 H-2 3.72, H-1 2.75: 2.63 Hz 
H-2 3.72 H-1 2.98 H-2 3.72 H-1 2.98  





















H (ppm) H (ppm) H (ppm) H (ppm)  
H-1 2.92 H-13.15 H-1 2.92 H-1 3.15 H-2 3.81, H-1 2.92:  4.01 Hz 
H-2 3.81 H-1 2.92 H-4 4.05 H-4 4.41 H-2 3.81, H-1 3.15: 2.66 Hz 
H-2 3.81 H-1 3.15 H-2 3.81 H-1 2.92  
H-4 4.05 H-4 4.41 H-2 3.81 H-4 4.05  






































































































































IV. CONCLUSIONS AND FUTURE WORK 
 
 In the previous work, model compound syntheses provided a viable  
 
synthetic strategy for the synthesis of analog 4. The coupling of aldehyde 24 and  
 
alkyne 29 was the most challenging step in the synthesis of this analog. The  
 
other challenge encountered was the insolubility of the free primary alcohol in  
 
solvents necessary for the final synthesis of the analog. Despite the difficulties in  
 
finding the correct protecting group and its removal without epoxide ring opening,  
 
the final result proved to be promising. While failures and complications arose  
 
throughout the research, it was possible to generate a compound that mimics the  
 
functionality of hydramycin.  
 
 The synthetic route provided in this dissertation gives a platform to expand  
 
this strategy to apply in the synthesis of hydramycin (1). If the synthesis were to  
 
start with the commercially available 1,8-dihydroxy-3-methylanthraquinone  
 
(Scheme 30), the challenge would be to selectively run the allylation reaction   
 




























hindered by the methyl group unlike the 8-hydroxyl group in the anthraquinone. It  
 




Scheme 31 shows the future work for the synthesis of hydramycin (1).  
 
The reaction would begin by reaction of commercially available halo quinone and  
 
electron-rich diene with chromium oxide in toluene to achieve cycloaddition to  
 
give phenol 48.41 Protection of the phenol with a silyl group would give 49.  
 
TBDPS is a stable protecting group for phenols and would be easily removed in  
 
later stages. Reaction of the halo quinone 49 with commercially available methyl  
 
3-methyl-2-butenoate would give the anthraquinone 50.40 Allylation of the  
 
hydroxyanthraquinone as described earlier would give 51. Further reaction would  
 
give the aldehyde 52. Coupling with the alkyne would provide 53 and synthetic  
 




















































































A. General Methods 
 
 
Analytical TLC was performed on aluminum-backed plates coated with E. Merck  
 
silica gel, and detection was by irradiation by 254 nm UV light and/or charring  
 
with p-anisaldehyde dip. Column chromatography was run by using silica gel,  
 
63–200 mesh. 1H and 13C NMR spectra were acquired at 25 °C on a Varian  
 
Mercury 300, at 300 MHz and 75 MHz, respectively, or a Varian Inova 600  
 
instrument at 600 MHz and 150 MHz, respectively. Chemical shifts were reported  
 
as δ (ppm) values. All 2D NMR experiments (gCOSY, HSQC, HMBC and  
 
TOCSY) were acquired on the Varian Inova 600. Mass spectra were determined  
 
on a Micromass VG Quattro II Electrospray Ionization for low-resolution. High- 
 
resolution mass spectra were run on quadruple time of flight (Q-Star TOF) in the  
 






B. Preparation of 3-((tert-butyldimethylsilyloxy)methyl)pent-1-en-4-yn-3-ol  
 
      (5) 
 
 
Preparation of 2-(benzyloxy)acetic acid (11) 
 
Sodium metal (5.4 g, 0.23 mol) was added to 108 mL of benzyl alcohol in  
 
portions at 100 °C. After all of the sodium had reacted, the sodium salt of  
 




reaction was heated to 165 °C and stirred for 48 h. The excess benzyl alcohol  
 
was distilled off at 0.25 mm Hg and 40 °C. Water was added to the sticky  
 
residue, and the resulting solution was extracted with ether. The aqueous layer  
 
was brought to pH 2 by addition of 2 M HCl, and the solution was extracted with  
 
ether. The combined ether extracts were dried over MgSO4 and concentrated.  
 
The pale yellow residue was distilled at 0.1 mm Hg and 120 °C (Lit.42  135-140  
 
°C at 0.24 mm Hg) to give 28 g (0.17 mmol, 81%) of 11 as a colorless oil.1H  
 
NMR (CDCl3): δ 4.09 (s, 2H), 4.58 (s, 2H), 7.20 (m, 5H), 10.68 (br s, 1H). 13C  
 
NMR (CDCl3): δ 66.57, 73.41, 128.17, 128.22, 128.59, 136.66, 175.51. The NMR  
 
spectra matched with those previously reported.43 
 
 
Preparation of 2-(benzyloxy)-N-methoxy-N-methylacetamide (12) 
 
A solution of 2-(benzyloxy)acetic acid (11, 4.70 g, 28.3 mmol) and 1,1’- 
 
carbonyldiimidazole (5.10 g, 30.9 mmol) dissolved in 200 mL of dry THF was  
 
stirred until no more CO2 evolved. Next N,O-dimethylhydroxylamine  
 
hydrochloride (3.10 g, 30.9 mmol) was added, and the reaction was stirred at  
 
room temperature for 48 h. The solution was filtered, and the filtrate was diluted  
 
with ether, then washed with 1 N HCl and brine. The organic layer was dried over  
 
MgSO4 and concentrated. Distillation at 0.1 mm Hg and 110–115 °C (Lit.44 132  
 
°C at 0.2 mm Hg) gave 3.80 g of the product 12 (18.2 mmol, 64%) as a yellow oil.  
 
1H NMR (CDCl3): δ 3.13 (s, 3H), 3.52 (s, 3H), 4.21 (s, 2H), 4.63 (s, 2H), 7.22 (m,  
 
5H). 13C NMR (CDCl3) δ 61.37, 67.31, 73.21, 127.82, 128.03, 128.42, 128.51,  
 




Preparation of 2-hydroxy-N-methoxy-methylacetamide (13) 
 
A solution containing 2-benzyloxy-N-methoxy-N-methylacetamide (12, 10.5 g,  
 
50.4 mmol) and 10% Pd/C (1.05 g) in 200 mL of abs EtOH was reacted  
 
with H2 gas at 40 psi for 24 h. The reaction mixture was filtered through Celite.  
 
The filtrate was concentrated yielding 5.76 g (46.5 mol, 97%) of 13 as a colorless  
 
oil. 1H NMR (CDCl3): δ 3.23 (s, 3H), 3.70 (s, 3H), 4.24 (s, 2H). 13C NMR (CDCl3):  
 








A solution containing 2-hydroxy-N-methoxy-N-methylacetamide (13, 4.70 g, 40.1  
 
mmol), TBSCl (6.35 g, 42.1 mmol) and imidazole (5.61 g, 82.4 mmol) and  
 
catalytic amount of DMAP in 20 mL of DMF was stirred overnight. The solution  
 
was diluted with 100 mL of water and extracted with EtOAc. The organic layer  
 
was washed with brine, dried over MgSO4 and concentrated. The crude material  
 
was purified via silica gel chromatography (3:1 petroleum ether–EtOAc) yielding  
 
7.96 g (33.2 mmol, 83%) of 14 as a pale-yellow oil. 1H NMR (CDCl3): δ 0.11 (s,  
 
6H), 0.92 (s, 9H), 3.18 (s, 3H), 3.67 (s, 3H), 4.43 (s, 2H). 13C NMR (CDCl3): δ – 
 
5.06, 18.76, 25.53, 31.97, 61.10, 61.50, 172.20. The NMR spectra matched  
 
with those previously reported.46 
 




To a solution containing trimethylsilylacetylene (7.5 mL, 53 mmol) in 170 mL of  
 
 59
THF cooled to -78 °C was added a 2.5 M solution of n-BuLi in hexane (11.4 mL,  
 
29.0 mmol). The reaction was stirred at -78 °C for 30 min. Next, a solution  
 
containing 2-(tert-butyldimethylsiyloxy)-N-methoxy-N-methylacetamide 14 (6.0 g,  
 
26 mmol) in 5 mL of THF was added. The reaction was allowed to warm to -10  
 
°C. The reaction was then cooled to -78 °C, and 2 mL of HOAc was added. After  
 
the reaction was warmed to 0 °C, brine and ethyl ether were added. The organic  
 
layer was extracted  with ethyl ether, dried over MgSO4 and concentrated.  
 
Purification via silica gel chromatography (4:1 petroleum ether–EtOAc) gave 5.6  
 
g (2.0 mmol, 87%) of 15 as a yellow-to-brown oil. 1H NMR (CDCl3): δ 0.09 (s,  
 
9H), 0.21 (s, 6H), 0.92 (s, 9H), 4.16 (s, 2H). 13C NMR (CDCl3): δ -5.06, -0.90,  
 
18.36, 25.69, 69.87, 99.85, 101.23, 186.61. The NMR spectra matched with  
 
those previously reported.46 
 
 




To a solution containing 1-(tert-butyldimethylsilyloxy)-4-trimethylsilylbut-3- 
 
yn-2-one (15, 1.0 g, 3.7 mmol) in 10 mL of THF was added 1.0 M  
 
vinylmagnesium bromide in THF (4.5 mL, 4.5 mmol), and the solution was stirred  
 
for 30 min. The reaction mixture was quenched with satd aq NH4Cl solution and  
 
extracted with EtOAc. The organic layer was dried with MgSO4 and concentrated  
 
to give 0.97 g (3.2 mmol, 86%) of 16 as a yellow oil that was used without  
 
purification. 1H NMR (CDCl3): δ 0.11 (s, 9H), 0.12 (s, 6H), 0.90 (s, 9H), 3.16 (br s,  
 




-5.12, -0.05, 18.30, 25.78, 70.19, 71.85, 89.80, 104.97, 116.71, 137.14. The  
 
NMR spectra matched with those previously reported.46 
 
 
Preparation of 3-((tert-butyldimethylsilyloxy)methylpent-1-en-4-yn-3-ol (5) 
 
To a solution containing 3-(tert-butyldimethylsilyloxymethyl)-5-trimethylsilylpent- 
 
1-en-4-yn-3-ol (16, 0.97 g, 3.2 mmol) in MeOH was added catalytic amount of  
 
K2CO3. The reaction was stirred for 1 h at room temperature. Satd aq NH4Cl was  
 
added, and the reaction mixture was extracted with EtOAc. The organic layer  
 
was dried over MgSO4 and concentrated. The crude material was purified via  
 
silica gel chromatography (9:1 petroleum ether–EtOAc) to give 0.62 g (0.28  
 
mmol, 86%) of 5 as a pale yellow oil. 1H NMR (CDCl3): δ 0.067 (s, 3H), 0.088 (s,  
 
3H), 0.89 (s, 9H), 2.48 (s, 1H), 3.17 (br s, 1H), 3.54 (d, J = 9.6 Hz, 1H), 3.65 (d, J  
 
= 9.4 Hz, 1H), 5.24 (d, J = 10.31 Hz, 1H), 5.58 (d, J = 17.12 Hz, 1H), 5.85 (dd, J  
 
= 10.31, 17.13 1H). 13C NMR (CDCl3): δ -5.12, 18.30, 25.75, 70.11, 71.36, 73.41,  
 





C. Preparation of 1-(methoxymethoxy)-9,10-dioxo-diydroanthacene-2- 
 
          carbaldehyde (22) 
 
 
Preparation of 1-(allyloxy)anthracene-9,10-dione (22) 
 
To a solution containing 1-hydroxyanthraquinone (2.5 g, 11 mmol), KI (0.92 g,  
 
5.5 mmol) and K2CO3  (15.6 g, 114 mmol) in 350 mL of DMF was added allyl  
 




completion, the reaction mixture was filtered. The solution was concentrated, and  
 
the crude material was purified via silica gel chromatography (9:1 petroleum  
 
ether–EtOAc) to give 2.86 g (10.8 mmol, 97%) of 22 as a yellow solid product.1H  
 
NMR (CDCl3): δ 4.76 (m, 2H), 5.38 (d, J = 1.59 Hz, 1H), 5.67 (d, J = 17.22 Hz  
 
1H), 6.13 (m, 1H), 7.30 (d, J = 8.45 Hz, 1H), 7.71 (m, 3H). 7.95 (dd, J = 1.09 Hz,  
 
7.69 Hz, 1H), 8.23 (m, 2H). 13C NMR (CDCl3): δ 70.21, 118.47, 119.69, 120.19,  
 
122.01, 126.77, 127.46, 132.35, 132.67, 133.41, 134.46, 135.04, 135.25, 135.95,  
 




Preparation of 2-allyl-1-hydroxyanthracene-9,10-dione (19) 
 
A solution containing Na2S2O4 (0.50 g, 1.9 mmol) in 150 mL of water and 50 mL  
 
of DMF was heated to 110 °C. To this was added a solution containing 1- 
 
(allyloxy)anthracene-9,10-dione (22, 0.50 g, 1.9 mmol) in 100 mL of DMF. The  
 
reaction was refluxed for 3 h. The reaction mixture was cooled for 2 h, and the  
 
crystals that formed were filtered and dried to give 0.49 g  (1.9 mmol, 98%) of  
 
19 as a yellow solid product. 1H NMR (CDCl3): δ 3.52 (d, J = 6.62 Hz, 2H), 5.16  
 
(d, 2H), 6.02 (m, 1H), 7.54 (d, J = 7.72 Hz, 1H), 7.79 (m, 3H), 8.29 (m, 2H), 13.00  
 
(s, 1H). 13C NMR (CDCl3): δ 33.81, 115.47, 117.08, 119.32, 126.87, 127.30,  
 
131.60, 133.24, 133.70, 134.01, 134.57, 134.84, 136.47, 136.57, 160.57, 182.33,  
 
182.92. The NMR spectra matched with those previously reported.47 
 
Preparation of 2-allyl-1-methoxymethoxyanthraquinone (20) 
 
A solution containing 2-allyl-1-hydroxyanthraquinone (19, 2.77 g, 10.5 mmol) in  
 
75 mL of CH2Cl2 was stirred with diisopropylethylamine (18.8 mL, 108 mmol) for  
 
 62
5 min. Chloromethyl methyl ether (5.8 mL, 76 mmol) was added, and the reaction  
 
mixture was refluxed overnight. The reaction mixture was quenched with satd aq  
 
NH4Cl solution, and the layers were separated. The organic layer was washed  
 
with brine, 1 M HCl, dried over MgSO4 and concentrated to give 2.9 g (9.4 mmol,  
 
90%) of a yellow solid that was used without purification. 1H NMR (CDCl3): δ 3.62  
 
(d, J = 6.61 Hz, 2H), 3.65 (s, 3H), 5.14 (m, 1H), 5.18 (m, 1H), 5.19 (s, 2H), 6.01  
 
(m, 1H), 7.64 (d, J = 7.96 Hz, 1H), 7.78 (m, 2H), 8.10 (d, J = 8.1 Hz, 1H), 8.25  
 
(m, 2H). 13C NMR (CDCl3): δ 35.60, 57.96, 102.32,117.49, 119.30,  126.93,  
 
127.45, 130.16, 132.92, 133.89, 134.41, 134.96, 135.79, 136.74, 136.81, 142.96,  
 




Preparation of 1-methoxymethoxy-2-propenylanthraquinone (21) 
 
A solution containing 2-allyl-1-hydroxyanthracene-9,10-dione (20, 2.5 g, 8.1  
 
mmol) and bis(acetonitrile)dichloropalladium(II) (0.2 g, 0.8 mmol) in 75 mL of  
 
CH2Cl2 was refluxed overnight. The reaction mixture was cooled and  
 
concentrated, and the crude material was purified by flash chromatography (2:1  
 
petroleum ether–EtOAc) to give 2.3 g (7.9 mmol, 95%) of 21 as an orange solid  
 
product. 1H NMR (CDCl3): δ 1.99 (d, J = 6.69 Hz, 3H), 3.64 (s, 3H), 6.43 (s, 2H),  
 
6.42 (m, 1H),  6.96 (d, J = 15.95 Hz, 1H), 7.78 (m, 3H), 7.87 (d, J = 8.22 Hz, 1H),  
 
8.10 (d, J = 8.20 Hz, 1H), 8.25 (m, 2H). 13C NMR (CDCl3): δ 19.42, 58.21,  
 
101.91, 124.01, 125.50, 126.90, 127.41, 130.15, 131.38, 132.96, 133.86, 133.98,  
 
134.34, 135.03, 136.82, 140.13, 154.84, 183.04, 183.11. The NMR spectra  
 
matched with those previously reported.46 
 
 63




A solution containing 1-methoxymethoxy-2-propenylanthraquinone (21, 1.00 g,  
 
2.71 mmol) was cooled to -78 °C. Ozone was passed into the solution until it  
 
turned greenish-blue. Nitrogen gas was bubbled through the solution to ensure  
 
removal of excess ozone. After the greenish-blue color disappeared, 3 mL of  
 
methyl sulfide was added with stirring. The solution was concentrated, and the  
 
product was purified on a silica gel column (5:1 petroleum ether–EtOAc) to give  
 
0.81 g (2.3 mmol, 85%) of 22 as a yellow solid. 1H NMR (CDCl3): δ 3.63 (s, 3H),  
 
5.31 (s, 2H), 7.86 (m, 3H), 8.32 (m, 3H), 10.6 (s, 1H). 13C NMR (CDCl3) δ 20.12,  
 
56.31, 117.40, 118.66, 127.14, 127.69, 128.32, 132.85 (2C), 133.26, 134.67,  
 
135.26, 137.16, 164.47, 181.81, 187.98, 188.87. The NMR spectra matched  
 
with those previously reported.46 
 
 
D. Preparation of 1-hydroxy-9,10-dioxo-9,10-dihydroanthracene-2- 
              
             carbaldehyde (24) 
 
Preparation of 1-hydroxy-2-(prop-1-enyl)anthracene-9,10-dione (23) 
 
A solution containing 2-allyl-1-hydroxyanthracene-9,10-dione (19, 0.50 g, 1.9  
 
mmol) and bis(acetonitrile)dichloropalladium(II) (49 mg, 0.19 mmol) in 75 mL  
 
of CH2Cl2 was refluxed overnight. The reaction mixture was cooled and  
 
concentrated, and the crude material was purified by flash chromatography (2:1  
 
petroleum ether–EtOAc) to give 0.47g (1.8 mmol, 95%) of 23 as an orange solid  
 




6.40 Hz, 1H), 7.78 (m, 4H), 8.29 (m, 2H), 13.19 (s, 1H). 13C NMR (CDCl3): δ  
 
19.26, 115.90, 119.52, 124.03, 126.88, 127.27, 131.25, 131.29, 132.43, 133.24,  
 
133.73, 133.76, 133.94, 134.61, 159.60, 182.09, 189.05. The NMR spectra  
 
matched with those previously reported.47 
 




A solution of 1-hydroxy-2-(prop-1-enyl)anthracene-9,10-dione (23, 0.45 g, 1.7  
 
mmol) dissolved in 100 mL of CH2Cl2 was cooled to -78 °C. Ozone was passed  
 
into the solution until it turned greenish-blue. Nitrogen gas was bubbled through  
 
the solution to ensure removal of extra ozone. After the greenish-blue color  
 
disappears, 3 mL of methyl sulfide was added with stirring. The solution was  
 
concentrated and the product was purified on a silica gel column (9:1 Petroleum  
 
ether: EtOAc) to give  0.39 g (1.5 mmol, 88%) of the yellow product. 1H NMR  
 
(CDCl3): δ 7.81, (m, 3H), 8.23 (m, 3H), 10.56 (s, 1H), 13.2 (s, 1H). 13C NMR  
 
(CDCl3): δ 117.40, 118.66, 127.14, 127.69, 128.32, 132.85 (2C), 133.26, 134.67,  
 
135.26, 137.16, 164.47, 181.81, 187.98, 188.87. The NMR spectra matched  
 
with those previously reported.48 
 
 
E. Synthesis of 1-hydroxy-2-(methoxy(methyl)amIno)anthracene-9,10-dione  
 
    (26) 
 








formic acid was added 1-hydroxy-9,10-dioxo-9,10-dihydroanthracene-2- 
 
carbaldehyde (24, 0.20 g, 0.80 mmol) at room temperature, and the mixture was  
 
stirred for 3 h. Water was added to the reaction mixture. The aqueous solution  
 
was extracted with CH2Cl2, dried over MgSO4 and concentrated to give 0.17 g  
 
(0.63 mmol, 79%) of 25 as a yellow solid product that was used without further  
 
purification. 1H NMR (CDCl3): δ 7.81, (m, 3H), 8.23 (m, 3H), 10.38 (br s, 1H),  
 
10.69 (s, 1H). 13C NMR (CDCl3): δ 115.02, 117.69, 118.66, 127.14, 127.69,  
 
128.32, 133.01 (2C), 133.26, 134.67, 136.33, 137.16, 164.47, 187.98, 188.87.  
 
The NMR spectra matched with those previously reported. 48 
 
 




A solution 1-hydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (25,  
 
0.15 g, 0.56 mmol) and 1,1’-carbonyldiimidazole (0.10 g, 0.62 mmol) dissolved in  
 
50 mL of dry THF was stirred until no more CO2 evolved. Next N,O- 
 
dimethylhydroxylamine hydrochloride (60 mg, 0.62 mmol) was added, and the  
 
reaction was stirred at room temperature for 48 h. The solution was filtered, and  
 
the filtrate was diluted with ether, then washed with 1 N HCl and brine. The  
 
organic layer was dried over MgSO4 and concentrated. The crude product was  
 
purified via silica gel chromatography (2:1 petroleum ether–EtOAc) to give 0.16 g  
 
(0.51 mmol, 92%) of 26 as a bright-yellow product. 1H NMR (CDCl3): δ 4.20 (s,  
 
3H), 4.63 (s, 3H), 7.81, (m, 3H), 8.23 (m, 3H), 10.77 (s, 1H). 13C NMR (CDCl3): δ  
 




134.67, 135.26, 137.16, 164.45, 168.44, 187.98, 188.90. 
 
 
F. Preparation of 3-(benzyloxymethyl)pent-1-en-4-yn-3-ol (29) 
 
 
Preparation of 1-(benzyloxy)-4-(trimethylsilyl)but-3-yn-2-one (27) 
 
To a solution of trimethylsilylacetylene (5.2 mL, 40.0 mmol) in 100 mL of THF  
 
cooled to -78 °C was added 2.5 M solution of n-BuLi in hexane (8.4 mL, 21.0  
 
mmol). The reaction was stirred for 30 min at 78 °C. A solution of 2-(benzyloxy)- 
 
N-methoxy-N-methylacetamide (12, 4.0 g, 19.1 mmol) in 50 mL of THF was  
 
added and the reaction was warmed to 0 °C. Upon cooling to -78 °C, the reaction  
 
was quenched with 1 mL of concentrated HOAc. The solution was warmed to 0  
 
°C, and 50 mL of brine and 50 mL of ether were added. The organic layer was  
 
separated, and the aqueous layer was washed with ether. The combined organic  
 
layer was dried over MgSO4 and concentrated. The crude material was purified  
 
by silica gel chromatography (4:1 petroleum ether–EtOAc) to give 3.5 g (14  
 
mmol, 74%) of 27 as a brown oil. 1H NMR (CDCl3): δ 0.24 (s, 9H), 4.23 (s, 2H),  
 
4.64 (s, 2H), 7.37 (m, 5H). 13C NMR (CDCl3): δ -0.88, 73.34, 75.71, 99.71,  
 
101.27, 127.92, 128.02, 128.47, 137.01, 184.66. The NMR spectra matched  
 
with those previously reported.49 
 
 




To a solution of 1-(benzyloxy)-4-(trimethylsilyl)but-3-yn-2-one (27, 2.0 g, 8.1  
 




mL,9.7 mmol). The solution was stirred at room temperature for 1 h. The reaction  
 
was quenched with satd aq NH4Cl and extracted with EtOAc, dried over  
 
MgSO4, and concentrated to give 2.1 g (7.6 mmol, 94%) of 28 as a brown oil  
 
that was used without further purification. 1H NMR (CDCl3): δ 0.19 (s, 9H), 2.92  
 
(br s, 1H), 3.49 (d, J = 9.41 Hz, 1H), 3.58 (d, J = 9.43 Hz, 1H), 4.68 (s, 2H), 5.27  
 
(d, J = 10.30 Hz, 1H), 5.63 (d, J = 17.09 Hz, 1H), 5.91 (dd, J = 10.30 Hz, J =  
 
17.09 Hz, 1H), 7.35 (m, 5H). 13C NMR (CDCl3): δ -0.15, 71.09, 73.55, 76.42,  
 
90.56, 104.54, 116.69, 127.60, 127.75, 128.40, 137.30, 137.76. The NMR  
 
spectra matched with those previously reported.49 
 
 
Preparation of 3-(benzyloxymethyl)pent-1-en-4-yn-3-ol (29) 
 
 
A solution containing 3-(benzyloxymethyl)-5-(trimethylsilyl)pent-1-en-4-yn-3-ol  
 
(28, 2.1 g, 7.6 mmol) was dissolved in MeOH, and a catalytic amount of K2CO3  
 
was added. The reaction was allowed to stir at room temperature for 1 h. The  
 
reaction was quenched with satd aq NH4Cl and extracted with EtOAc. The  
 
organic extract was dried over MgSO4 and concentrated. The crude material was  
 
purified via silica gel chromatography (9:1 petroleum ether–EtOAc) to give 1.4 g  
 
(6.9 mmol, 91%) of 29 as a yellow oil. 1H NMR (CDCl3): δ 2.59 (s, 1H), 2.98 (br s,  
 
1H), 3.47 (d, J = 9.42 Hz, 1H), 3.59 (d, J = 9.44 Hz, 1H), 4.67 (s, 2H), 5.30 (d, J =  
 
10.30 Hz, 1H), 5.68 (d, J = 17.10 Hz, 1H), 5.92 (dd, J = 10.30 Hz, J = 17.10 Hz,  
 
1H), 7.35, (m, 5H). 13C NMR (CDCl3): δ 71.87, 73.31, 74.00, 83.27, 116.98,  
 





G. Synthesis of 2-(1-(benzyloxy)-2-hydroxybut-3-en-2-yl)-1H-naphtho[2,3- 
 
       h]chromene-4,7,12-trione (33) 
 
 




A solution containing 3-(benzyloxymethyl)pent-1-en-4-yn-3-ol (29, 0.13 g, 0.64  
 
mmol) in 10 mL of THF was cooled to -78 °C. To the solution was added 2.5 M  
 
solution of n-BuLi in hexane (0.5 mL, 1.3 mmol). The reaction was allowed to  
 
slowly warm to 0 °C over 3 h. The solution was cooled to -78 °C, and 1- 
 
methoxymethoxy-9,10-dioxo-9,1-dihydroanthracene-2-carbaldehyde (22, 0.13 g,  
 
0.42 mmol) was added. The acetone–dry ice bath was removed, and the  
 
reaction was stirred at room temperature for 20 min. The reaction was quenched  
 
with satd aq NH4Cl, and the reaction mixture was extracted with CH2Cl2. The  
 
organic layer was dried over MgSO4 and concentrated. The crude product was  
 
purified via silica gel chromatography (2:1 petroleum ether–EtOAc) to give 42 mg  
 
(60 μmol, 20%) of 30 as a dark-red oily product. 1H NMR (CDCl3): δ 1.98 (br  
 
s, 2H), 3.55 (d, 2H),  3.63 (s, 3H), 4.66 (s, 2H), 5.30 (m, 1H), 5.31 (s, 2H), 5.63  
 
(d, 1H), 5.91 (s, 1H), 5.92 (m, 1H), 7.32 (m, 5H), 7.83 (m, 3H), 8.00 (m, 1H), 8.26  
 
(m, 2H). 13C NMR (CDCl3) δ 20.12, 56.31, 60.17, 71.19, 73.97, 76.75, 83.98,  
 
86.79, 116.20, 117.33, 119.70, 127.20, 127.72, 127.96 (2C), 128.14, 128.71  
 
(2C), 133.28, 133.81, 134.48, 134.98, 135.14, 135.33, 137.22, 137.27,  
 
137.75,160.05, 171.44, 182.26, 189.16. HRESIMS: Calcd for C30H24O7 m/z  
 








A solution containing 3-(benzyloxymethyl)pent-1-en-4-yn-3-ol (29, 0.61 g, 3.0  
 
mmol) in 10 mL of THF was cooled to -78 °C. To the solution was added 2.5 M  
 
solution of n-BuLi in hexane (2.4 mL, 6.0 mmol). The reaction was allowed to  
 
slowly warm to 0 °C over 3 h. The solution was cooled to -78 °C and 1-hydroxy- 
 
9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde (24, 0.31 g, 1.2 mmol) was  
 
added. The acetone–dry ice bath was removed, and the reaction was stirred at  
 
room temperature for 20 min. The reaction was quenched with satd aq NH4Cl,  
 
and the reaction mixture was extracted with CH2Cl2. The organic layer was dried  
 
over MgSO4 and concentrated. The crude product was purified via silica gel  
 
chromatography (2:1 petroleum ether–EtOAc) to give 0.29 g (0.64 mmol, 53 %)  
 
of 31 as a dark red oily product. 1H NMR (CDCl3): δ 1.98 (br s, 2H), 3.53 (m, 2H),  
 
4.64 (s, 2H), 5.27 (m, 1H), 5.67 (s, 1H), 5.88 (s, 1H), 5.89 (m, 1H), 7.30 (m, 5H),  
 
7.78 (m, 3H), 7.97 (m, 1H), 8.25 (m, 2H), 13.01 (s, 1H).  13C NMR (CDCl3): δ  
 
60.17, 71.19, 73.97, 76.75, 83.98, 86.79, 116.20, 117.33, 119.70, 127.20,  
 
127.72, 127.96 (2C), 128.14, 128.71 (2C), 133.28, 133.81, 134.48, 134.98,  
 
135.14, 135.33, 137.22, 137.27, 137.75,160.05, 171.44, 182.26, 189.16.  
 















To a solution containing 2-(4-(benzyloxymethyl)-1,4-dihydroxyhex-5-en-2-ynyl)-1- 
 
hydroxyanthracene-9,10-dione (31, 0.29 g, 0.64 mmol) in 20 mL of CH2Cl2 was  
 
added MnO2 (0.82 g, 9.4 mmol). The reaction was stirred for 1 h. The mixture  
 
was filtered through Celite and concentrated to give 0.24 g (0.53 mmol, 83%) of  
 
32 as a dark-orange oil that was used without purification. 1H NMR (CDCl3): δ  
 
2.80 (br s, 1H), 3.53 (m, 2H), 4.62 (s, 2H), 5.31 (d, J = 10.27 Hz, 1H), 5.66 (d, J =  
 
17.06 Hz, 1H), 5.88 (dd, J = 17.11 Hz, J = 10.26 Hz, 1H), 7.32 (m, 5H), 7.83 (m,  
 
2H), 8.10 (m, 2H), 8.30 (m, 2H), 12.1 (s, 1H). 13C NMR (CDCl3): δ 71.51, 74.08,  
 
76.29, 84.19, 94.32, 116.20, 117.33, 119.70, 127.20, 127.72, 127.96 (2C),  
 
128.14, 128.71 (2C), 133.28, 133.81, 134.48, 134.98, 135.14, 135.33, 137.22,  
 
137.27, 137.75,160.05, 175.10, 182.26(2C), 189.16. HRESIMS: Calcd for  
  
C28H20O6 m/z 452.1260; [M + H]+ m/z 453.1313 (calcd 453.1344). 
 
 




To a solution of 2-(4-(benzyloxymethyl)-4-hydroxyhex-5-en-2-ynyl)-1- 
 
hydroxyanthracene-9,10-dione (32, 0.24 g, 0.53 mmol) in dry acetone was  
 
added K2CO3 (0.15 g, 1.1 mmol). The reaction was refluxed overnight. The  
 
reaction mixture was filtered and concentrated. The crude material was purified  
 
by silica gel chromatography (2:1 petroleum ether–EtOAc) to give 0.12 g (0.27  
 




(d, J = 9.21 Hz, 1H), 4.48 (m, 2H), 4.62 (d, J = 12.23 Hz, 1H), 5.36 (d, J = 10.71  
 
z, 1H), 5.70 (d, J = 17.25 Hz, 1H), 6.23 (dd, J = 10.77 Hz, 17. 28 Hz, 1H), 6.81  
 
(s, 1H), 7.06 (m, 5H), 7.85 (m, 2H), 8.25 (m, 2H), 8.33 (d, J = 8.34 Hz, 1H), 8.59  
 
(d, J = 8.25 Hz, 1H). 13C NMR (CDCl3): δ 73.49, 73.88, 76.73, 109.41, 117, 73,  
 
123.28, 127.37, 127.53, 127.96, 128.05, 128.45, 132.16, 134.31, 134.31, 134.97,  
 
135.56, 138.50, 138.61, 154.35, 171.84, 177.11, 180.99, 182.55. HRESIMS:  
 





H. Synthesis of 4-ethynyl-2,2-dimethyl-4-vinyl-1,3-dioxolane (37) 
 
 
Synthesis of 1-hydroxy-4-(trimethylsilyl)but-3-yn-2-one (34) 
 
To a solution of trimethylsilylacetylene (6.50 mL, 50.4 mmol) in 75 mL of THF  
 
cooled to -78 °C was added 2.5 M solution of n-BuLi in hexane (13.4 mL, 33.6  
 
mmol). The reaction was stirred for 30 min at 78 °C. A solution of 2-hydroxy-N- 
 
methoxy-N-methylacetamide (13, 2.10 g, 16.8 mmol) in 25 mL of THF was added  
 
and the reaction was warmed to 0 °C. Upon cooling to -78 °C, the reaction was  
 
quenched with 1 mL of glacial HOAc. The solution was warmed to 0 °C, and 50  
 
mL of brine and 50 mL of ether were added. The organic layer was separated,  
 
and the aqueous layer was washed with ether. The combined organic layer was  
 
dried over MgSO4 and concentrated. The crude material was purified by silica gel  
 
chromatography (1:1 petroleum ether–EtOAc) to give 2.10 g (13.4 mmol, 80%) of  
 
34 as a brown oil. 1H NMR (CDCl3): δ 0.24 (s, 9H), 4.23 (s, 2H), 5.29 (t, 1H). 13C  
 
NMR (CDCl3): δ -0.64, 60.57, 100.08, 101.29.  
 
 72
Synthesis of 2-((trimethylsilyl)ethynyl)but-3-ene-1,2-diol (35) 
 
To a solution containing 1-hydroxy-4-(trimethylsilyl)but-3-yn-2-one (34, 2.00 g,  
 
12.8 mmol) in 5 mL of THF was added 1.0 M vinylmagnesium bromide in THF  
 
(38.4 mL, 38.4 mmol), and the solution was stirred for 30 min. The reaction  
 
mixture was quenched with satd aq NH4Cl solution and extracted with EtOAc.  
 
The organic layer was dried with MgSO4 and concentrated to give 2.20 g (11.9  
 
mmol, 93.2%) of 35 as a yellow oil that was used without purification. 1H NMR  
 
(CDCl3): δ 0.16 (s, 9H), 3.10 (br s, 1H), 3.51 (d, J = 11.1 Hz, 1H), 3.63 (d, J =  
 
11.1 Hz, 1H), 5.27 (d, J = 10.30 Hz, 1H), 5.27 (t, 1H), 5.60 (d, J = 17.1 Hz, 1H),  
 
5.88 (dd, J = 17.1, J = 10.31 Hz, 1H). 13C NMR (CDCl3): δ 0.057, 69.90, 72.53,  
 
91.69, 104.28, 117.23, 137.33. 
 
 
Synthesis of 2-ethynylbut-3-ene-1,2-diol (36) 
 
 
To a solution of 2-(4-(benzyloxymethyl)-4-hydroxyhex-5-en-2-ynoyl)-1- 
 
hydroxyanthracene-9,10-dione (35, 2.10 g, 11.4 mmol) in dry MeOH was added  
 
K2CO3  (1.60 g, 12.0 mmol). The reaction was allowed to stir at room temperature  
 
for 1 h. The reaction was quenched with satd aq NH4Cl and extracted with  
 
EtOAc. The organic extract was dried over MgSO4 and concentrated. The crude  
 
material was purified via silica gel chromatography (3:1 petroleum ether–EtOAc)  
 
to give 1.20 g (10.7 mmol, 94%) of 36 as a yellow solid. 1H NMR (CDCl3): δ  
 
2.59 (s,1H), 3.10 (br s, 1H), 3.55 (d, J = 11.1 Hz, 1H), 3.66 (d, J= 11.1 Hz, 1H),  
 
5.26 (t, 1H), 5.29 (d, J = 10.3 Hz, 1H), 5.63 (d, J = 17.1 Hz, 1H), 5.89 (dd, J =  
 






Synthesis of 4-ethynyl-2,2-dimethyl-4-vinyl-1.3-dioxolane (37) 
 
To a solution containing 2-ethynylbut-3-ene-1,2-diol (36, 0.26 g, 2.4 mmol) in  
 
acetone at 0 °C was added 2-methoxypropene and catalytic amount of PPTS.  
 
The reaction was run for over 2 h at 0 °C. The reaction was quenched with solid  
 
NaHCO3 and the acetone was evaporated. Water was added to the crude  
 
material, and the aqueous mixture was extracted with EtOAc. The organic layer  
 
was dried over MgSO4 and  Concentrated, and the crude product was purified via  
 
silica gel chromatography (9:1 petroleum ether–EtOAc) to give 2.4 g (1.6 mmol,  
 
67%) of 37 as a yellow oil product.  1H NMR (CDCl3): δ 1.54 (s, 3H), 1.55 (s, 3H),  
 
3.51 (s, 1H), 3.88 (s, J = 11.2 Hz, 1H), 3.92 (d, J = 11.1 Hz, 1H), 5.23 (br s), 5.25  
 
(d, J = 10.3 Hz, 1H) 1H), 5.67 (d, J = 17.2 Hz, 1H), 5.89 (dd, J = 17.1 Hz, J = 0.3  
 
Hz 1H). 13C NMR (CDCl3): δ 26.61, 26.84, 75.58, 75.60, 84.30, 86.44, 111.73,  
 
117.64, 136.84. HRESIMS: Calcd for C9H12O2 m/z 152.1904; [M + Na]+ m/z  
 
175.0735 (calcd 175.0749). 
 
 










A solution containing 3-(benzyloxymethyl)pent-1-en-4-yn-3-ol (37, 0.15 g, 0.97  
 
mmol) in 10 mL of THF was cooled to -78 °C. To the solution was added a  
 
 74
solution of 2.5 M n-BuLi in hexane (0.39 mL, 0.97 mmol). The reaction was  
 
allowed to slowly warm to 0 °C over 3 h. The solution was cooled to -78 °C, and  
 
1-hydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde (24, 97 mg,  
 
0.39 mmol) was added. The acetone–dry ice bath was removed and the reaction  
 
was stirred at room temperature for 20 min. The reaction mixture was quenched  
 
with satd aq NH4Cl, solution and the mixture was extracted with CH2Cl2. The  
 
organic layer was dried over MgSO4 and concentrated. The crude product was  
 
purified via silica gel chromatography (4:1 petroleum ether–EtOAc) to give 73.4  
 
mg (0.180 mmol, 47%) of 38 as a dark-red oily product. 1H NMR (CDCl3): δ 1.54  
 
(s, 3H), 1.55 (s, 3H), 3.89 (d, J = 8.40 Hz 1H), 4.26 (d, J = 8.39 Hz, 1H), 5.27 (d,  
 
J = 10.07 Hz, 1H), 5.67 (d, J = 17.02 Hz, 1H), 5.91 (s, 1H), 5.92 (m, 1H), 7.83 (m,  
 
3H), 7.98 (d, 1H), 8.31 (m, 2H), 12.1 (s, 1H). 13C NMR (CDCl3): δ 26.61, 26.84,  
 
71.19, 73.97, 76.75, 83.98, 86.79, 116.20, 117.33, 119.70, 127.20, 127.72,  
 
127.96 (2C), 128.14, 128.71 (2C), 133.28, 133.81, 134.48, 134.98, 135.14,  
 
135.33, 137.27, 137.75, 160.05, 171.44, 182.26, 189.16. HRESIMS: Calcd for  
 
C24H20O6 m/z 404.1260; [M + Na]+ m/z 427.1082 (calcd 427.1158); [M + K]+ m/z  
 
443.0823 (calcd 443.0897). 
 
 





To a solution containing (38, 46.1 mg, 0.110 mmol) in 10 mL of CH2Cl2 was  
 
added MnO2 (0.143 g,  1.64 mmol) and was stirred for 2 h. The mixture was  
 
filtered through Celite and concentrated to give 42 mg (0.10 mmol, 92%) of 39  
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as an orange oil that was used without purification. 1H NMR (CDCl3): δ 1.48 (s,  
 
3H), 1.61 (s, 3H), 3.97 (d, J = 8.62 Hz, 1H), 4.40 (d, J = 8.60 Hz, 1H), 5.38 (d, J =  
 
10.13 Hz, 1H), 5.76 (d, J = 16.85,1H), 5.93 (dd, J = 10.05 Hz, J = 17.06 Hz,1H),  
 
7.85-7.87 (m, 3H), 8.33-8.35 (m, 3H), 12.1 (s, 1H). 13C NMR (CDCl3): δ 26.64  
 
(2C), 71.51, 74.08, 76.29, 84.19, 94.32, 116.20, 117.33, 119.70, 127.20, 127.72,  
 
127.96 (2C), 128.14, 133.28, 134.48, 134.98, 135.14, 135.33, 137.22, 137.27,  
 
137.75, 175.10, 189.16. HRESIMS: Calcd for C24H18O6 m/z 402.1103; [M + Na]+  
 
m/z 425.0924 (calcd 425.1001), [M + K]+ m/z 441.0672 (calcd 441.0740). 
 
 





To a solution of (39, 18 mg, 0.042 mmol) in dry acetone was added a catalytic  
 
amount of K2CO3. The reaction was refluxed overnight. The reaction mixture was  
 
filtered and concentrated. The crude material was purified via silica gel  
 
chromatography (4:1 petroleum ether–EtOAc) to give 16 mg (0.041 mmol, 90%)  
 
of 40 as a yellow oily solid. 1H NMR (CDCl3): δ 1.55 (s, 3H), 1.58 (s, 3H), 1H),  
 
4.28 (d, J = 8.62 Hz, 1H), 4.82 (d, J = 8.60 Hz, 1H), 5.34 (d, J = 10.13 Hz, 1H),  
 
5.65 (d, J = 16.85, 1H), 6.44 (dd, J = 10.05 Hz, J = 17.06 Hz, 1H), 6.78 (s, 1H),  
 
7.82-7.87 (m, 3H), 8.29-8.37 (m, 2H), 8.60 (d, 1H). 13C NMR (CDCl3): δ 26.64  
 
(2C), 71.51, 76.29, 84.19, 94.32, 109.17, 116.20, 117.33, 119.70, 127.20,  
 
127.72, 127.96 (2C), 128.14, 133.28, 134.48, 134.98, 135.14, 135.33, 137.22,  
 
137.27, 137.75, 175.10, 189.16. HRESIMS: Calcd for C24H18O6 m/z 402.1103; [M  
 
+ H]+ m/z 403.1103 (calcd 403.1182), [M + Na]+ m/z 425.0899 (calcd 425.1001) 
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A solution containing (33, 0.11 g, 0.24 mmol) and FeCl3 (0.16 g, 0.98 mmol) in  
 
10 mL CH2Cl2 was stirred at room temperature for 6 h. The reaction was  
 
quenched with water, extracted with CH2Cl2, dried over MgSO4, and  
 
concentrated. The residue was purified via silica gel chromatography (1:1  
 
petroleum ether–EtOAc) to give 86 mg (0.23 mmol, 96%) of 41 as a yellow solid.  
 
1H NMR (CDCl3): δ 2.60 (br s, 1H), 3.79 (d, J = 11.64 Hz, 1H), 4.33 (d, J = 11.60  
 
Hz, 1H), 5.06 (t, 1H), 5.39 (d, J = 10.75 Hz, 1H), 5.66 (d, J = 17.23, 1H), 6.15  
 
(dd, J = 10.78 Hz, J = 17.25 Hz, 1H), 6.66 (s, 1H), 7.79 (m, 2H), 8.23 (m, 2H),  
 
8.30 (d, J = 8.32 Hz, 1H), 8.54 (d, J = 8.24 Hz, 1H). 13 C NMR (DMSO) δ 67.97,  
 
78.31, 109.49, 116.99, 122.95, 123.20, 127.14, 127.50, 127.99, 131.73, 132.56,  
 
134.65, 134.92, 135.63, 138.05, 138.22, 154.45, 173.49, 176.55, 181.40, 182.65.  
 














mmol) and a catalytic amount of DMAP was added TBSCl (30.7 mg, 0.204  
 
mmol). The reaction was stirred overnight at 30 °C. The mixture was quenched  
 
with satd aq K2CO3, extracted with CH2Cl2, dried over MgSO4, and concentrated.  
 
The crude material was purified via silica gel chromatography (2:1 petroleum  
 
ether–EtOAc) to give 47 mg (0.099 mmol, 97%) of a yellow oily solid. 1H NMR  
 
(CDCl3) δ 0.08 (s, 3H), 0.061 (s, 3H), 0.76 (s, 9H), 3.51 (br s, 1H), 3.78 (d, J =  
 
9.80 Hz, 1H), 4.60 (d, J = 9.80 Hz, 1H), 5.37 (d, J = 10.80 Hz, 1H), 5.73 (d, J  
 
=17.28 Hz, 1H), 6.26 (dd, J = 10.79 Hz, J = 17.27 Hz, 1H), 6.81 (s, 1H), 7.84 (m,  
 
2H), 8.29 (m, 2H), 8.35 (d, J = 8.2 Hz, 1H), 8.61 (d, J = 8.25 Hz, 1H). 13C NMR  
 
(CDCl3) δ -3.36, 18.33, 25.86, 68.13, 76.82, 109.68, 117.69, 122.14, 123.36,  
 
127.37, 127.52, 128.60, 132.29, 132.47, 132.61, 134.34, 134.49, 134.62, 135.01,  
 
135.44, 138.00, 154.41, 172.26, 177.01, 181.63, 182.31. HRESIMS: Calcd for  
 
C27H28O6Si m/z 476.1655; [M + H]+ m/z 477.1553 (calcd 477.1733), [M + Na]+  
 
m/z 499.1553 (calcd 499.1553). 
 
 





To a solution containing (43, 32 mg, 0.066 mmol) in 5 mL of dry CH2Cl2 was  
 
added m-CPBA (45.8 mg, 0.265 mmol) in 5 mL of dry CH2Cl2. The reaction was  
 
run at 40 °C under aspirator vacuum on a rotary evaporator (~ 30–40 torr). The  
 
reaction was quenched with satd sodium thiosulfate, and extracted with  
 
CH2Cl2. The organic extracts were dried over MgSO4 and concentrated. The  
 
crude product was purified via silica gel chromatography (3:1 petroleum ether:  
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EtOAc) to give 32 mg (0.065 mmol, 98%) of a mixture of diastereomer as a  
 
yellow oily solid. Diastereomer 44A: Rf 0.35 (3:1 petroleum ether–EtOAc); 1H  
 
NMR (CDCl3): δ 0.024 (s, 3H), 0.059 (s, 3), 0.82 (s, 9H), 2.50 (br s, 1H), 2.79 (dd,  
 
J = 2.63 Hz, J = 5.33 Hz, 1H), 2.99 (dd, J = 4.06 Hz, J = 5.34 Hz, 1H), 3.76 (dd, J  
 
= 2.63 Hz, J = 4.04 Hz, 1H), 4.16 (d, J = 10.02 Hz, 1H), 4.49 (d, J = 10.02 Hz,  
 
1H), 6.81 (s, 1H), 7.89 (m, 2H), 8.33 (m, 2H), 8.38 (d, J = 8.26 Hz, 1H), 8.64 (d, J   
 
= 8.27 Hz, 1H). 13C NMR (CDCl3): δ -5.37, -5.26, 18.38, 25.88, 42.64, 53.27,  
 
66.94, 74.23, 110.57, 123.54, 127.41, 127.56, 128.36, 132.30, 132.47, 134.46,  
 
135.08, 137.96, 154.20, 170.23, 176.88, 181.78, 182.36. HRESIMS: Calcd for  
 
C27H28O7Si m/z 492.1604; [M]+ m/z 492.1650.   
 
Diastereomer 44B: Rf 0.34 (3:1 petroleum ether–EtOAc);  1H NMR (CDCl3): δ  
 
0.03 (s, 3H), 0.06 (s, 3H), 0.79 (s, 9H), 2.49 (br s, 1H), 2.92 (dd, J = 4.05 Hz, J =  
 
5.05 Hz, 1H), 3.16 (dd, J = 2.66 Hz, J = 5.07 Hz, 1H), 3.81 (dd, J = 2.65 Hz, J =  
 
4.01 Hz, 1H), 4.05 (d, J = 10.01 Hz, 1H), 4.41 (d, J = 10.01 Hz, 1H), 6.83 (s, 1H),  
 
7.84 (m, 2H), 8.33 (m, 2H), 8.37 (d, J = 8.24 Hz, 1H), 8.63 (d, J = 8.24 Hz, 1H).  
 
13C NMR (CDCl3): δ -5.38, -5.24, 18.39, 25.86, 43.98, 53.63, 65.85, 74.95,  
 
111.00, 123.48, 127.41, 127.51, 128.46, 132.34, 134.39, 135.02, 138.10, 154.48,  
 
176.64, 181.88, 182.56. HRESIMS: Calcd for C27H28O7Si m/z 492.1604; [M]+ m/z  
 
492.1640.   
 
 





To a solution of (44A, 60.6mg, 0.123 mmol) in dry THF cooled to 0 °C was  
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added 1.0 M solution TBAF in THF (25 µL, 0.25 mmol). The reaction was  
 
stirred for 30 min at 0 ºC. The reaction mixture was concentrated, and the crude  
 
material was purified via silica gel chromatography (1:2 petroleum ether–EtOAc)  
 
to give 43.2 mg of 4A as a yellow solid product (11.4 mmol, 92%). 1H NMR  
 
(DMSO-d6): δ 2.59 (br s, 1H), 2.84 (m, 1H), 2.98 (m, 1H), 3.67 (m, 1H), 3.80 (d,  
 
J = 11.60 Hz, 1H), 4.01 (d, J = 11.61 Hz, 1H), 5.04 (t, 1H), 6.59 (s, 1H), 7.91 (m,  
 
2H), 8.18 (m, 2H), 8.23 (d, J = 8.24 Hz, 1H), 8.47 (d, J = 8.24 Hz, 1H). 13C NMR  
 
(DMSO-d6): δ  42.50, 52.99, 67.01, 74.23, 110.67, 123.54, 127.41, 127.71,  
 
128.36, 132.35, 132.40, 134.01, 135.12, 137.96, 154.27, 170.23, 176.88, 181.66,  
 
183.11. HRAPPIMS: Calcd for C21H14O7 m/z 378.0740; [M]+ m/z 378.0740. 
 
 




To a solution of (44B, 16.0 mg, 0.032 mmol) in dry THF cooled to 0 °C was  
 
added 1.0 M solution TBAF in THF (60 µL, 0.064 mmol). The reaction was  
 
stirred for 30 min at 0 ºC. The reaction mixture was concentrated, and the crude  
 
material was purified via silica gel chromatography (1:2 petroleum ether–EtOAc)   
 
to give 12 mg of 4B as a yellow solid product (3.1 mmol, 96%). 1H NMR  
 
(DMSO-d6): δ 2.55 (br s, 1H), 2.78 (m, 1H), 2.96 (m, 1H), 3.70 (m, 1H), 3.91 (d, J  
 
= 11.64 Hz, 1H), 4.26 (d, J = 11.65 Hz, 1H), 5.12 (t, 1H), 6.68 (s, 1H), 8.02 (m,  
 
2H), 8.29 (m, 2H), 8.33 (d, J = 8.26 Hz, 1H), 8.57 (d, J = 8.26 Hz, 1H). 13C NMR  
 
(DMSO-d6): δ 44.12, 53.89, 65.79, 75.07, 111.09, 123.48, 127.41, 127.51,  
 








K. Synthesis of 2-hydroxy-2-(oxiran-2-yl)-2-(4,7,12-trioxo-7,12-dihydro-4H- 
 
naphtho[2,3-h]chromen-2-yl)ethyl 4-bromobenzoate (47A,B) 
 
 
Synthesis of 2-hydroxy-2-(4,7,12-trioxo-7,12-dihydro-4H-naphtho[2,3- 
 
h]chromen-2-yl)but-3-enyl 4-bromobenzoate (46) 
 
To a stirred solution of (41, 21 mg, 0.058 mmol) in CH2Cl2 was added Et3N,  
 
followed by 4-bromobenzoyl chloride at room temperature. The resultant mixture  
 
was stirred for 3 h. The reaction mixture was washed with aq NaHCO3 solution.  
 
The organic layer was dried using MgSO4 and concentrated. The residue was  
 
purified by silica gel chromatography (2:1 petroleum ether–EtOAc to 1:1  
 
petroleum ether–EtOAc) to give 28 mg (0.050 mmol, 87%) of 46 as a yellow  
 
product. 1H NMR (CDCl3): δ 2.03 (br s, 1H), 4.80 (d, J = 11.62 Hz, 1H), 5.03 (d, J  
 
= 11.62 Hz, 1H), 5.51 (d, J = 10.69 Hz, 1H), 5.83 (d, J = 17.19 Hz, 1H), 6.48 (dd,  
 
J = 10.67 Hz, J = 17.14 Hz, 1H), 6.83 (s, 1H), 7.51 (m, 4H), 7.77 (d, J = 8.67 Hz,  
 
1H), 7.85 (m, 3H), 8.32 (m, 2H), 8.36 (d, J = 8.26 Hz, 1H), 8.58 (d, J = 8.27 Hz,  
 
1H). 13C NMR (CDCl3): δ 69.63, 76.44, 109.47, 118.71, 122.62, 127.38, 127.61,  
 
128.15, 128.27, 128.45, 129.03, 131.42, 131.81, 132.06, 132.33, 132.40, 132.54,  
 
132.58, 132.71, 134.38, 136.27, 137.98, 144.60, 166.48, 171.40, 176.98, 181.32,  
 








Synthesis of 2-hydroxy-2-(oxiran-2-yl)-2-(4,7,12-trioxo-7,12-dihydro-4H- 
 
naphtho[2,3-h]chromen-2-yl)ethyl 4-bromobenzoate (47A,B) 
 
To a solution containing 46 (25 mg, 0.046 mmol) in dry CH2Cl2 of 5 mL was  
 
added m-CPBA (32.0 mg, 0.183 mmol) in 5 mL of dry CH2Cl2. The reaction was  
 
run at 40 °C under aspirator vacuum on a rotary evaporator (~30–40 torr). The  
 
reaction was quenched with satd sodium thiosulfate, and extracted with CH2Cl2.  
 
The organic extracts were dried over MgSO4 and concentrated. The crude  
 
product was purified via silica gel chromatography (3:1 petroleum ether–EtOAc)  
 
to give 25 mg (0.044 mmol, 97%) of a mixture of diastereomers as a yellow  
 
solid. Diastereomer A: Rf 0.34 (2:1 petroleum ether–EtOAc); 1H NMR (CDCl3): δ  
 
2.33 (br s, 1H), 2.83 (dd, J = 2.62 Hz, J = 4.94 Hz, 1H), 2.91 (dd, J = 4.01 Hz, J =  
 
5.00 Hz, 1H), 4.03 (dd, J = 2.62 Hz, J = 3.96 Hz, 1H), 4.83 (d, J = 11.64 Hz, 1H),  
 
4.95 (d, J = 11.61 Hz, 1H), 6.90 (s, 1H), 7.56 (m, 4H), 7.77 (d, J = 8.67 Hz, 1H),  
 
7.80 (m, 3H), 8.27 (m, 2H), 8.36 (d, J = 8.26 Hz, 1H), 8.61 (d, J = 8.27 Hz, 1H).  
 
13C NMR (CDCl3): δ 44.03, 53.02, 66.98, 73.48, 110.74, 123.75, 127.43, 128.32,  
 
131.55, 131.87, 131.97, 132.10, 132.26, 132.26, 134.46, 135.08, 137.84, 137.98,  
 
138.14, 138.28, 154.39, 166.13, 168.18, 171.43, 176.27, 181.27, 182.34.   
 
Diastereomer B: Rf 0.33 (2:1 petroleum ether–EtOAc);  1H NMR (CDCl3): δ 2.29  
 
(br s, 1H), 3.06 (dd, J = 4.03 Hz, J = 4.64 Hz, 1H), 3.16 (dd, J = 2.68 Hz, J = 4.83  
 
Hz, 1H), 4.16 (dd, J = 2.69 Hz, 3.91 Hz, 1H), 4.96 (d, J = 11.58 Hz, 1H), 5.10 (d,  
 
J = 11.57 Hz, 1H), 6.82 (s, 1H), 7.53 (m, 4H), 7.76 (d, J = 8.67 Hz, 1H), 7.83 (m,  
 
3H), 8.34 (m, 2H), 8.37 (d, J = 8.26 Hz, 1H), 8.58 (d, J = 8.27 Hz, 1H). 13C NMR  
 
(CDCl3): δ 42.70, 53.43, 68.94, 72.84, 109.99, 123.74, 127.43, 128.32, 131.55,  
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131.87, 131.97, 132.19, 132.26, 132.33, 134.46, 135.62, 137.84, 137.98, 138.19,  
 
















































Derivatization of Thiol-terminated Carbohydrates and 
Development of a Glycoconjugate Tool Set for the 





























A. Eukaryotes and Prokaryotes 
 
 
Animals, plants, fungi, and protists are eukaryotes. They are organisms  
 
with complex cell or cells and where the generic material is organized into a  
 
membrane-bound nucleus or nuclei. Animals, plants, and fungi are mostly  
 
multicellular, while many sorts of protists are unicellular. Eukaryotic cells also  
 
contain membrane-bound organelles such as mitochondria and choloroplasts.  
 
Unlike eukaryotes, prokaryotes are organisms without a cell  
 
nucleus, or any other membrane-bound organelles. Most are unicellular, but  
 
some prokaryotes are multicellular. They are divided into two domains: the  
 
bacteria and the archaea. They are usually much smaller than the eukaryotic  
 
cells. A distinction between prokaryotes and eukaryotes is that eukaryotes do  
 
have “true” nuclei containing their DNA on a tightly bound and organized  
 
chromosomes. Prokaryotes contain only a single loop of stable chromosomal  
 
DNA stores in an area called the nucleoid. Mitochondria and chloroplasts are  
 
Membrane-bound organelles in eukaryotes responsible in performing various  
 
metabolic processes; however, in prokaryotes similar processes occur across the  
 
cell membrane. The difference between the structure of prokaryotes and  
 
eukaryotes is so great that it is considered to be the most important distinction  
 
among the groups of organisms. Figures 1 and 2 show drawings of  
 

























 Both eukaryotic and prokaryotic cell surfaces present a complex set of  
 
glycoconjugates. Glycoconjugates contain carbohydrates covalently linked to  
 
another building block of nature, such as an amino acid (peptide) or a lipid.1,2   
 
Carbohydrates comprise a large group of molecules including simple sugars  
 
(monosaccharides), oligosaccharides, and polysaccharides. Complex  
 
carbohydrates occur in such glycoconjugates as glycoproteins, glycolipids, and  
 
proteoglycans. These molecules can serve as intermediates in generating  
 
energy, as signaling molecules, or as structural components. The structural roles  
 
of carbohydrates become particularly important in constructing complex  
 
multicellular organs and organisms, which require interactions of cells with one  
 
another and with the surrounding matrix. Indeed, all eukaryotic and prokaryotic  
 
cells in nature carry a dense and complex array of covalently attached sugar  
 
chain glycans. Since most glycans are on the outer surface of cellular and  
 
secreted macromolecules, they are in a position to modulate or mediate a wide  
 
variety of events in cell–cell, cell–matrix, cell–surface, cell–virus and cell– 
 
molecule interactions. These interactions mediate cell adhesion, cell motility, and  
 
cell-cell communication and recognition of toxins. They are also in position to  
 
mediate interactions between organisms, for example between host and parasite.  
 
Figure 3 shows most of the above-mentioned interactions. In addition, simple,  
 
highly dynamic protein-bound glycans are abundant in the cytoplasm of  
 








Figure 3. Cell–cell interactions, cell–matrix adhesion, cell–viral recognition and  
 




In naturally occurring glycoconjugates, the portion of the molecule  
 
comprising the glycans can vary greatly, from being very minor in an amount to  
 
being the dominant component. Indeed, it is striking that sugar chains make up a  
 
substantial portion of the mass of most glycoconjugates.3 Figure 4 represents  
 
the Thy-1 glycoprotein including the three N-glycans and glycophospholipid (GPI- 
 
glycan) anchor whose acyl chains would normally be embedded in the  
 
membrane bilayer. The polypeptide represents only a relatively small portion of  
 
the total mass of the protein. A reason for the dominant composition of glycans is  
 













coating of sugars, giving rise to the so-called glycocalyx. This-cell surface  
 
structure was first observed by electron microscopists many years ago (Figure  
 
5).  The figure shows the electron micrograph of endothelial cells from a blood  
 
capillary in the diaphragm muscle of a rat. The arrowhead particles are decorated  
 
on the vascular lumen side and are cationized ferritin with  pI 8.4.  These  
 
particles are binding with the acidic residues (sialic-acid-containing glycans and  
 
sulfated glycosaminoglycans) contained in the cell-surface glycocalyx. The figure  
 






Figure 5. Binding of acid containing glycans with cationized ferritin in the  
 




 Many natural bioactive molecules are glycoconjugates, and the attached  
 
glycans can have dramatic effects on stability, action, and turnover of these  
 
molecules in intact cells or organisms. For this reason alone, glycobiology and  
 
carbohydrate chemistry have become of increasing importance in modern  
 
biotechnology. In addition, many important biological interactions and functions  
 
mediated by glycans are potentially amenable to manipulation in vivo.  
 
Furthermore, several human diseases are characterized by changes in glycan  
 




2. Protein-glycan interactions 
 
 
 Nearly 100 crystal structures of glycan–protein complexes have been  
 
solved, and several complexes have been deduced by NMR spectroscopy. The  
 
common features of these complexes are that the glycan-binding sites are small  
 
and the interactions with proteins involve both hydrogen bonds to hydroxyl  
 
groups and hydrophobic interactions. Many different glycan-binding proteins  
 
have been described, and their interactions with glycans have been studied by a  
 
wide variety of approaches.5,6 
 
 The concept of glycans being specifically recognized by proteins dates  
 












refer to enzymes that recognize specific glycan substrates.7,8 The dream of  
 
specific interactions between sugars and proteins in three-dimensional space  
 
was realized by the determination of the crystal structure of lysozyme, which was  
 
the first “carbohydrate-binding protein” to be crystallized.9 Its structure was  
 













7) is an ellipsoidal protein with a deep cleft across part of its surface. Six  
 
saccharide units of the substrate fit into this cleft, cleaving it into a  
 
disaccharide and tetrasaccharide products. With so many oxygen atoms in  
 
sugars, up to 14 hydrogen bonds form between the substrate and enzyme. In  
 
addition, hydrophobic interactions help hold the substrate in position. Other  
 
glycan-binding proteins whose three-dimensional structures are of historical  
 
significance are concanavalin A (crystal structure reported in 1972)10,11 and  
 




3. Biological roles of glycans 
 
 
 The biological roles of glycans span the complete spectrum, from those  
 
that are relatively unimportant to those that appear crucial for the development,  
 
growth, functioning, or survival of the organism. Over the years, many theories  
 
have been advanced regarding the biological roles of glycans. Although the  
 
available evidence provides support for essentially all of these theories,  
 
exceptions to each can be easily found. This could be due to the enormous  
 
diversity of glycans in nature. Figure 8 shows the biological roles of glycans  
 
which can be broadly divided into two groups: one that relies on the structural  
 
and/or physical properties of the glycans and the other that relies on the specific  
 
recognition by other molecules (those involved in the recognition by endogenous  
 
receptors within the same organism and those involved In the recognition by  
 












a. Structural/physical roles of glycans 
 
 It is strongly believed that glycans have many protective, stabilizing, 
 
organizational, and barrier functions. The glycocalyx that covers most cells can  
 
represent a substantial physical barrier. The glycans attached to matrix  
 
molecules such as collagens and proteoglycans are important for the  
 
maintenance of tissue structure, porosity, and integrity. Such molecules also  
 
contain binding sites for specific types of glycans, which in turn help with the  
 
overall organization of the matrix. The external location of glycans on most  
 
glycoproteins can provide a general shield, protecting the underlying peptides  
 
from recognition by antibodies. Overall, these types of functions are obviously of  
 




b. Glycan roles in endogenous recognition 
 
 Many examples are now available of specific biological roles of glycans in  
 
cell–cell recognition and cell–matrix interactions. One of the best cases is that of  
 
the selectin family of adhesion molecules that mediate critical interactions among  
 
blood cells in a wide variety of normal and pathological situations. There is also a  
 
good evidence that egg–sperm binding involves the glycans on the egg’s  
 
surface.   
 
 Carbohydrate–carbohydrate interactions may also play a specific role in  
 
cell–cell interaction and adhesion. An example is the specific interactions of  
 





c. Glycan roles in exogenous recognition 
 
 Certain glycans act as specific receptors for a variety of viruses, bacteria,  
 
and parasites. They are also receptors for many plant and bacterial toxins and  
 
can serve as antigens for autoimmune reactions. For example, influenza virus  
 
hemagglutinins specifically recognize the type of sialic acid, its modifications, and  
 
its linkage to the underlying sugar chain, whereas several toxins bind with great  
 
specificity to certain glycans. Glycan sequences on soluble glycoconjugates,  
 
such as the secreted mucins, can also act as decoys for microorganisms and  
 
parasites. Thus, a pathogen or toxin seeking to bind to mucosal cell  
 
membranes might first encounter the specific oligosaccharide ligand attached to  
 




the cell below. In contrast, there are instances in which symbiosis between  
 
species is mediated by specific glycan recognition. An example is the bacteria  
 







 Early scientific investigations in the carbohydrate field focused on the  
 
chemistry, biochemistry, and biology of carbohydrates. However, during the  
 
initial phase of the modern revolution in molecular biology, studies of glycans  
 
lagged far behind those of other major classes of molecules, including nucleic  
 
acids and proteins. This was in large part due to the inherent structural  
 
complexity of glycans, the difficulty in easily determining their sequence, and the  
 
fact that their biosynthesis could not be directly predicted from the cell template.  
 
In addition, the mechanisms by which they are recognized remain poorly  
 
understood. Fortunately, advances in both carbohydrate synthesis,13,14  
 
nanoscale synthesis, and characterization have opened the possibility of  
 
emulating a critical subset of glycocalyx features. This dissertation will be about  
 



















Mimicking cell surfaces will offer insights into the question of how cells  
 
interact with proteins and other chemicals in the glycoconjugate environment.  
 
This will also give a valuable tool for understanding how cells are recognized and  
 
bound, and will pave the way for the use of  biosensor platforms in immunology,  
 
virology, developmental biology, cancer, biodefense and many other areas where  
 
recognition of cell-surface carbohydrates plays a central role. This dissertation  
 
will cover the developments, challenges and solutions in the following areas: 
 
1.  Derivatization of thiol-terminated mannose and galactose. The  
 
      carbohydrates produced will mimic the glycans on the cell surfaces and  
 
      provide a linker arm to the nano surface. 
 
2. Creation of a nano-patterned glycoarray surfaces for the placement of  
 
      ligands and presentation on carbohydrate recognition by lectins. Arrays    
 
      presenting carbohydrates from a single  surface will be developed. 
 
3. Fluorescence imaging. The synthetic carbohydrate landscapes will be  
  
      interrogated to assess their recognition by lectins. Fluorescence imaging   
 












1. Selection of target lectins and choices of ligands 
 
This dissertation focuses on a specific class of lectins, C-type lectins.  
 
These represent a large family of Ca2+ dependent lectins that share primary  
 
structural homology in their carbohydrate-recognition domains (CRD). This very  
 
large family is found throughout the animal kingdom. These lectins are involved  
 
in many immune-system functions, such as inflammation and immunity to tumor  
 
cells and virally infected cells. These features make them appealing for this  
 
dissertation. In selecting a group of C-type lectins, the criteria used were as  
 
follows: (1) the proteins should represent major ligand specificities, (2) they must  
 
be easily obtainable, and (3) finally proteins for which some level of biochemical  
 
characterization had been obtained are to be given priority. Mannose-binding  
 
lectin, MBL, was given top priority. The primary ligand for MBL is D-mannose,  
 
and it also recognizes N-acetyl-D-glucosamine and L-fucose. The crystal  
 
structure of trimeric rat mannose-binding protein A (MBP-A) complexed with  
 
mannose at 1.8 Å resolution is shown in Figure 9. Mannose is indicated in the  
 
stick figure and Ca2+ and Cl- are indicated by the green and blue balls,  
 
respectively. All the above-mentioned carbohydrates recognized by MBL have a  
 
common feature, the vicinal pairs of equatorial hydroxyl groups (Figure 10) that  
 
bind with the calcium ions of the lectin. Galactose, which has an axial OH at C-4,  
 
group is not recognized. Therefore, in this dissertation, two sugars will be  
 













































Mannose Glucose Fucose Galactose
R = OH, NHAc  
 
 










2. Control of nano-patterened microarray surfaces 
 
Not only must the composition of synthetic glycoconjugates be controlled,  
 
but ligand presentation must be controlled, paying close attention to the  
 
arrangement and density of ligands. For the initial period of investigation, most  
 
surface preparation and ligand cluster synthesis/immobilization will be performed  
 
manually. Various functional densities will be prepared on these surfaces by  
 






































A. Synthesis of Carbohydrates 
 
 
1. Synthesis of mannose derivative with an –SH terminus 
 
 
The first stage of the carbohydrate synthesis was done by a colleague,  
 
Brian Sanders. A simple thiol-terminated mannose derivative for linking to the  
 
template was synthesized. The route towards the final product initiated by  
 
acetylation of the free D-mannose as shown on Scheme 1. The treatment of  
 
penta-O-acetyl-D-mannopyranose with allyl alcohol in the presence of boron  
 
trifluoride diethyl ether complex as the Lewis acid produced allyl tetra-O-acetyl- 
 
D-mannopyranose (1). Compound 2 was synthesized by reaction with  
 












































A derivative with a tethered –SH terminus was synthesized using the  
 
robust procedure developed by Cummings and co-workers.15 This method is to  
 
efficiently derivatize free reducing glycans that exploits their reactivity with aryl  
 
amines and provide derivatives that are fluorescent and have primary amines for  
 
covalent modification. Scheme 2 shows the application of the Cummings  
 
















































Scheme 2. Derivatization of free glycan with DAP and introduction of the thiol- 
 




glycan can be efficiently derivatized directly with 2,6-diaminopyridine (DAP) to  
 
generate fluorescently labeled GDAP 3, which is the added feature. The Schiff  
 
base azomethine is reduced by sodium cyanoborohydride to a stable secondary  
 
amine. Reaction with 2-iminothiolane in phosphate buffer (PB) pH 7.8 was used  
 




 Zhou and co-workers reported that the thiol produced by the reaction of  
 
free amine with 2-iminothiolane is unstable under basic conditions.16 It was  
 
suggested that the thiol is stable at acidic pH, but at mildly basic pH it cyclizes to  
 
the intermediate shown in Figure 11. These workers developed a method to  
 
generate and trap the thiol using maleimide in acidic media. The unstable  
 
product produced from the reaction of the amine with 2-iminothiolane under basic  
 
basic pH, was collected in a vial containing N-methylmaleimide for coupling via a  
 
Michael addition reaction. TFA was used for the acidic pH, and HPLC analysis  
 
showed the presence of the maleimide product.16 
 
The above reported reaction was studied using inexpensive lactose as the  
 
disaccharide as shown in Scheme 3. The Cummings reaction was carried out   
 
using DAP to give 5. The reaction of the free aryl amine with 2-iminothiolane did  
 
indeed give the expected cyclized product 7. HRESIMS: Calcd for C21H34N4O10S+  
 
m/z 520.1959; [M + Na]+ m/z 543.1866 (calcd 543.1857).  Trapping the thiol with  
 
maleimide was not necessary, since a free –SH terminus was needed for linking  
 





























Figure 11. Proposed mechanism for the formation of unstable thiol product,  
 
                  which is stable at acidic pH and  trapping of  the thiol using N-   
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3. Derivatization using the Kamerling method 
 
 The thiol-containing chain must be introduced at the reducing end of the  
 
lactose. Reductive amination is a well-documented and robust chemical method.  
 
Therefore, the cysteamine moiety was introduced into the free disaccharide using  
 
the Kamerling method as shown in Scheme 4.17 Prior to the reductive amination  
 
reaction, the thiol functional group in cysteamine was protected with a trityl group  
 
(compound 8) to avoid side reactions. Reaction of 8 with lactose produced 9. The  
 
trityl protecting group was smoothly removed under mild acidic conditions (ionic  
 


























































 The robust chemistry for the introduction of the thiol-containing  
 
cysteamine onto free glycans, together with the  facile purification protocols of  
 
the thiol-containing glycans were the characteristics that ensured success for the  
 
method. As a result, the protocol was applied to 1,3-α-D-mannobiose as shown  
 



























































B. Creation of a Nano-patterned Glycoarray Surfaces for the Introduction of 
 
Ligands and Carbohydrates 
 
 
1. Modular ligand clusters 
 
 Once the thiol-terminated sugars were derivatized, the next step was the  
 
presentation of the carbohydrates onto the reactive surfaces. To study the  
 
molecular aspects of the presentation, a glycoconjugate “tool set” was proposed.  
 
Such a “tool set” is a diverse set of tetherable carbohydrate ligand clusters in  
 
which different features, particularly linker length, are varied in concert with the  
 
carbohydrate ligands. The overall architecture of the modular design is shown in  
 
Figure 12. Ligand clusters will be assembled from three fundamental  
 
components: ligands, i.e., the specific carbohydrate structures that bind the  
 








Figure 12. Architecture of modular ligand clusters.  
 
 108
linkers which connect the ligands to the nodes and control the region of space to  
 
which the ligands have access. The combination of nodes with linkers, plus short  
 
adapters to introduce ligand-reactive groups, forms a chemically defined  
 
template to which the ligands are attached for presentation. Clusters will be  
 
immobilized on surfaces through the intermediacy of a tether to provide  
 
clearance from the surface and to control the scope of interaction possible  
 
between adjacent clusters on the surface.  
 
 Polyvalent interactions dictate the avidity of lectins for glycoconjugate  
 
decorated surfaces. The capability of lectins to recognize patterns is well  
 
documented,18,19 and plays a central role in their ability to carry out host  
 
recognition processes in vivo.19 This higher order function makes controlled  
 
and repeatable ligand presentation crucial to the development of synthetic  
 
carbohydrate arrays used to study lectin function. The ligand “tool set” developed  
 
provides multivalent templates and ligands that, when assembled, have  
 
characteristic spacing and mobilities dictated by the nodes and linkers.  
 
 
2. Assembly of ligand clusters on the surface 
 
 Carbohydrates have been presented from a wide variety of solid  
 
substrates for analysis or to enhance bioactivity. Materials include polymers,20  
 
glass,21,22 metals,23,24 and self-assembled monolayers.25-29 Arrays presenting  
 
diverse carbohydrates from a single surface are being developed rapidly and  
 
have been the subject of several recent reviews.30-33 The surface chemistry  
 




assembled monolayer approach described by Mrksich and co-workers.25,26,34 
 
 A limited “tool set” of compounds for the modular assembly of  
 
carbohydrate ligand clusters was prepared. The objective was to form all the  
 
linkages shown as squares (diamonds) in Figure 12 on the surface, allowing the  
 
automated, combinatorial, in situ assembly of different templates. As shown in  
 
Figure 13, linkers and tethers were joined to each other, and clusters were  
 
attached to surfaces, using amide bonds formed through standard peptide  
 
chemistry. The carbohydrate groups were joined to the tether assemblies via  
 
thioether linkages. For this purpose, a short chain terminated in a thiol in the  
 
reducing end of the carbohydrate structures as shown earlier was used. The  
 
thiol-modified carbohydrates were then reacted with maleimide rings introduced  
 











































Figure 13. Schematic chemical structure of the presentation template and  
 
complete, immobilized ligand cluster 
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works very well in water, in which the carbohydrate ligands are readily soluble  
 
and where the final assembly of the clusters is anticipated. A large number of  
 
commercial reagents incorporating the maleimide function are available, and the  
 
thiol addition to maleimides has been successfully employed for the  
 
immobilization of mannose on the self-assembled monolayer, SAM.19  
 
 The choice of the linker structure was governed by a combination of  
 
factors, primarily the known or anticipated geometry of the lectin multimers, the  
 
need for structures that have good water solubility and resistance to non-specific  
 
protein adsorption, and the desire to use readily available amino acid derivatives  
 
that can be incorporated readily into the modular architecture. Linkers derived  
 
from PEG were used, which are hydrophilic and flexible. A number of amino acid  
 
derivatives having defined number of ethylene glycol EG (1, 2, 3, 4, 6, 8, 12 or  
 
24) within them are commercially available, allowing for segmental construction  
 
of chains having any desired number of EG units. The optimum length of the  
 
linker will need to be tuned for each ligand, and this is one of the major variables  
 
to be explored. It was estimated that the optimum linker length for  
 
monosaccharides will be between 4 and 12 EG units, and the initial goal was to  
 
construct templates using bifunctional PEG reagents (maleimide/NHS ester)  
 
having 4, 8, and 12 EG units (commercially available from Pierce). These  
 









3. Preparation of reactive surfaces and presentation of ligands 
 
 
 Various functional densities on the surface was prepared by mixing  
 
maleimide terminated reagents, the reactive sites, and methoxy terminated  
 
reagents, the unreactive sites to control the scope of interaction possible  
 
between adjacent clusters on the surface. The ligand tool to be developed will  
 
provide multivalent templates and ligands that, when assembled, have  
 
characteristic spacing and mobilities dictated by the linkers. Polyethylene glycol  
 
(PEG) reagents used with maleimide and methoxy terminus are maleimide- 
 
PEOn-NHS esters with n = 4, 8, 12 (Figure 14) and methyl-PEOn-NHS esters with  
 
n = 4, 8, 12 (Figure 15), respectively. Reactive maleimide PEG reagents were  
 
used as cross-linkers that each contain an NHS-ester, and unlike the methyl  
 














n = 4, 8, 12 
 
 











n = 4, 8, 12 
 
 
Figure 15. Structure of methyl-PEOn-NHS esters 
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ligands. Scheme 6 shows the preparation of reactive surfaces for sugar thiols.   
 
Amine-functionalized glass slides purchased from Erie Scientific were used.  The  
 
slides were created with a custom mask to produce 4 x arrays of spots. PEO- 
 
esters were implemented on the functionalized surfaces using robust chemistry,  
 
a Michael addition reaction.35 Solutions of NHS-esters were prepared by  
 
dissolving them in DMF (200 mM) and then diluting 10-fold with 4 M N,N-DIPEA  
 
in DMF. Serial dilutions from 100% maleimide were then prepared, and amine  
 
functionalized slides were manually immobilized starting with a 100% reactive  
 
maleimide terminus as shown in Figure 16. Unreacted amines were acetylated  
 


































Figure 16. Immobilization of surfaces with various functional densities of PEG  
 
                      reagents 
 
 
 Arrays presenting monosaccharide conjugate 2 were next prepared  
 
(Scheme 7). The arrays were prepared by applying the thiol sugar 2 solution (50  
 
mM solution in phosphate buffer pH 7.5) to the surfaces presenting varying  
 
densities of the reactive maleimide groups and unreactive methoxy groups. The  
 
















































Scheme 7. Preparation of carbohydrate arrays via thioether linkages 
 
 
4. Recognition by lectin and fluorescence imaging 
 
Human serum mannose-binding lectin (MBL) was the main object of our  
 
studies. The native protein is commercially available (U.S Biological). The  
 
synthetic carbohydrate landscapes will be interrogated to assess their recognition  
 
by lectins. Fluorescence imaging provides a rapid, convenient method to assess  
 
overall avidity for lectins. For fluorescence determinations, the MBL was labeled  
 
with conventional amine-reactive fluorophore  
 
[5(and6)carboxytetramethylrhodamine, succinimidyl ester] (5(6)-TAMRA, SE).  
 


































Scheme 8. Reaction of TAMRA with amines 
 
 
Labeled lectin was presented on the array in the presence of 5 mM CaCl2, since  
 
it has Ca2+-dependent interaction with mannose on the ligand cluster shown in  
 
Scheme 7. The array was incubated and humidified in a chamber, and the  
 
excess labeled MBL was washed away with buffer. However, imaging of the  
 
array with a laser scanner did not show the expected fluorescence (Figure 17).  
 





Figure 17. Fluorescent image of the resulting arrays. The image reveals that the  
 
                  MBL did not associate specifically with the carbohydrate ligands in the  
                   
                   array.  
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5. Functionalization of glass slides and preparation of reactive surface 
 
 Commercial amine-functionalized slides are unstable and hydrolyze when  
 
exposed to air with time. The slides were tested by the treatment with reactive  
 
dye TAMRA in phosphate buffer pH 7.5. Figure 18 shows the image with non  
 
consistent fluorescence on the arrays. It was necessary to freshly prepare amine- 
 
functionalized slides was as shown in Figure 19 before immobilization with  
 
clusters. Glass slides, purchased from Erie Scientific (4 x 10 array spots), were  
 
first activated using ethanolic sodium hydroxide solution. Amino-silanization of  
 
glass slides with 2% 3-aminopropyltrimethoxysilane (APTMS) in 95% ethanol  
 
gave the appropriate amine-functionalized surfaces.  
 
 Surfaces were then tested by labeling the surface with the amine-reactive  
 
dye, TAMRA. Laser scan array imaging showed a high and consistent  
 
fluorescence (Figure 20). Alternative rows of arrays were acetylated before  
 




Figure 18. Laser scanner image of commercial amine functionalized slides after  
                    








































 Inexpensive sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1- 
 
carboxylate (Sulfo-SMCC) was used as the cross-linker as it contains the same  
 
functionality as the PEG reagents, an N-hydroxysuccinimide (NHS) and a  
 
maleimide group (Figure 21). Amine-functionalized slides were treated with a  
 
solution of NHS-ester and N,N-DIPEA in NMP for 1 h (Scheme 9). Unreacted  
 
amines were quenched with acetic anhydride in pyridine. Reaction of sulfo- 
 
SMCC with the surface was analyzed with 2-mercaptoethylamine hydrochloride.  
 
Labeling the surface with TAMRA after treatment of thiol with maleimide  
 
functionalization showed no fluorescence in the laser array scanner (Figure 22).  
 



































































Figure 22. TAMRA labeling of sulfo-SMCC functionalized arrays: acetylated  
 
                      amine surfaces were used as negative controls; however, the laser  
 
                      array scanner imaging showed the similar fluorescence as the  
 




 Sulfo-SMCC is water soluble, and it was reported that NHS-ester in sulfo- 
 
SMCC reacts with amines in aqueous solution with pH 7.5.36 Phosphate  
 
buffer–NMP (1:1, pH 7.5) was then used instead of 100% NMP and overnight  
 
treatment of sulfo-SMCC with amine-functionalized slides in a humidified  
 
chamber gave maleimide-functionalized slides (Scheme 10), followed by  
 
acetylation of unreacted amines.  Treatment (2 h) with the ligand 2- 
 
mercaptoethylaminehydrochloride as described before successfully gave amine- 
 
terminated clusters. The arrays on the slide were tested by labeling with TAMRA  
 





















































Scheme 10. Successful TAMRA labeling of the 2-mercaptoethylamine introduced  
   










Figure 23. Fluorescent image of maleimide + amine surfaces and amine  
   




Carbohydrates were then joined to the tether via thioether linkages. The thiol- 
 
terminated mannoses 2 and 12 in phosphate buffer at pH 7.5 were introduced  
 
















































Scheme 11. Reaction of sulfo-SMCC maleimide with thiol-modified mannoses via  
                      
                     thioether linkages 
 
  
For fluorescence determinations, the MBL was labeled with the  
 
conventional amine-reactive fluorophore TAMRA. Labeled lectin was presented  
 
in the presence of 5 mM CaCl2 on the surfaces containing mannoses 2 and 12,  
 
and acetylated amines for negative control as shown in Scheme 11. The slides  
 
were incubated and humidified in a dark chamber at 25 °C and the excess  
 
labeled MBL was washed with NMP. Imaging of the array with a laser scanner  
 
showed the expected fluorescence (Figures 24 and 25). The images clearly  
 







Figure 24. Fluorescent image of sugar 2 surfaces and acetylated amine surfaces  
 





Figure 25. Fluorescent image of sugar 12 surfaces and acetylated amine  
 
                         surfaces treated with labeled MBL  
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 Experiments were run by Dr. Roberts Standaert to test the above  
 
observed Ca2+ dependent binding of MBL with the ligands. Thiol-terminated  
 
carbohydrate 12 was used. Arrays were treated with MBL + 50 mM mannose  
 
(which should block binding of the lectin with ligand), MBL + 5 mM EDTA (which  
 
should prevent binding of the lectin with the ligand), and MBL + 5 mM CaCl2  
 
(which should allow binding) as shown in Figure 26. Fluorescence imaging with a  
 
laser scanner shows no binding in the columns where mannose or the Ca2+  
 
binder, EDTA, (Figure 27) is present. The most binding was observed for the  
 
sugar-derivatized column with Ca2+ present. These results indicate the binding  
 
seen in Figures 24 and 25 was dependent on Ca2+, which was expected as the  
 









Figure 26. Treatment of slides with MBL + EDTA and MBL + mannose for  
 







Figure 27. Fluorescence image of the array with negative controls (EDTA and  
 
mannose) and Ca2+-dependent binding of MBL with sugar 12 
 
 
 The proposed glycoconjugate “tool set” of simple building blocks was  
 
constructed in the modular assembly of chemically defined carbohydrate ligand  
 
clusters. The compounds produced with the tool set are the novel chemical  
 
entities that mimic the clustering of carbohydrate structures on cell surfaces. The  
 
observed avidity of the MBL to the clusters (Figures 24 and 25) leads to the study  
 
of a number of lectins that have a diverse set of structures and functions. Further  
 
studies is to characterize the valency and strength of interactions, including  
 











IV. CONCLUSION AND FUTURE WORK 
 
 
Kamerling and co-workers developed a route to the introduction of a thiol- 
 
containing chain onto a sugar by reductive amination of sugars with cysteamine.  
 
The robust chemistry developed and facile purification methods of the thiol- 
 
containing carbohydrates had the essential characteristics for the method to be  
 
successful. A disaccharide was prepared by total synthesis, and, therefore, a  
 
new thiol-terminated monosaccharide 13 (Figure 28) was synthesized by a co- 
 
worker using the well-documented Kamerling procedure. 
  
Thiol-terminated disaccharides for linking to the template terminus are  
 
also being synthesized by reaction with ethanedithiol under free-radical  
 
conditions. These carbohydrates as shown in Figure 29 have two different  
 
branching patterns, that of an α-(1→3)-linked disaccharide 14 and that of an α- 
 















































14 15  
 
 
Figure 29. Structures of thiol-terminated mannoses that are α-(1→3)-linked 14  
 
and α-(1→2)-linked 15 disaccharides 
 
 
Assembly of templates and ligand clusters on array surfaces was the most  
 
challenging step to provide the ligand “tool set” developed. The sulfo-SMCC  
 
binding was successful in an aqueous environment, and, therefore, a robust  
 
protocol was developed for template and ligand construction on array surfaces.  
 
The protocol will be used in multivalent templates and ligand assembly with  
 
controlled spacings and mobilities dictated by linkers (Figure 30). The binding- 
 
site density of the ligand arrays will be controlled using self-assembled  
 
monolayers (SAMs) of n-alkanethiols on gold surfaces. Immobilization of ligand  
 
clusters using the protocol developed in this dissertation will yield arrays of ligand  
 
clusters arranged at different densities. These arrays will be evaluated using  
 
atomic force microscopy (AFM) during single experiments (Figure 31). The AFM  
 
will be outfitted with lectin-functionalized atomic force microscope tips and will be  
 
used to probe surface-displayed carbohydrate ligand clusters that are patterned  
 
at specific densities using SAMs to elucidate the effects of cluster size and  
 



































A.  Synthesis of Thiol-terminated Carbohydrates 
 




Fresh solutions of 0.5 M 2,6-diaminopyridine (DAP) and 0.5 M sodium  
 
cyanoborohydride in 7:3 DMSO:HOAc were prepared. Solutions of DAP (0.150  
 
mL, 25.6 mmol) and sodium cyanoborohydride (1.50 mL, 73.0 mmol) were added  
 
to 1,3-α-D-mannobiose (5.0 mg, 15 μmol). The reaction was incubated in a  
 
closed vial for 4 h in a heat block at 65 °C. The mixture was lyophilized and  
 
purified using reversed-phase chromatography (5% MeOH in water). The  
 
fractions were monitored by HPLC, and those containing the product were  
 
lypholized to give 2.9 mg (6.8 mmol, 45%) of 3 as a brown syrup that was kept in  
 
the freezer (-20 °C) wrapped with aluminum foil. 1H NMR (300 MHz, CD3OD): δ  
 
3.52 (m, 3H), 3.56 (m, 2H), 3.59 (m, 3H), 3.64 (m, 4H), 3.71 (m, 3H), 3.73 (m,  
 
2H), 4.90 (d, J = 1.49 Hz, 1H), 5.87 (dd, J = 7.48 Hz, J = 8.04 Hz, 2H), 7.24 (t, J  
 
= 8.05 Hz, 1H), 8.29 (br s, 3H). 13C NMR (300 MHz, CD3OD): δ 46.10, 60.41,  
 
61.25, 62.12, 69.44, 70.09, 70.94, 71.37, 73.31, 75.70, 81.14, 94.33, 95.89,  
 
102.61, 155.11, 155.71, 172.17. HRESIMS: Calcd for C17H29N3O10 m/z  
 
435.1853; [M + H]+ m/z 436.1892 (calcd 436.1931).   
 




Fresh solutions of 0.5 M 2,6-diaminopyridine (DAP) and 0.5 M sodium  
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cyanoborohydride in 7:3 DMSO:HOAc were prepared. Solutions of DAP (2.10  
 
mL, 25.6 mmol) and sodium cyanoborohydride (6.0 mL, 73 mmol) were added to  
 
lactose (20.0 mg, 58.0 μmol). The reaction was carried out in a closed flask for 4  
 
h at 65 °C. The mixture was lypholized and purified using silica gel  
 
chromatography (3:1 CH2Cl2:MeOH to remove DAP, 100% MeOH) to get the  
 
product. The fractions containing the product were lypholized to give 21.9 mg  
 
(50.3 μmol, 86%) of 5 as a brown syrup that was stored in the freezer (- 20 °C)  
 
wrapped with aluminum foil. 1H NMR (300 MHz, CD3OD): δ 3.31 (m, 3H), 3.34  
 
(m, 1H), 3.43 (m, 1H), 3.59 (m, 3H), 3.76 (m, 4H), 3.88 (m, 3H), 3.99 (m, 2H),  
 
4.55 (d, J = 7.10 Hz, 1H), 5.89 (dd, J = 8.41 Hz, J = 10.52 Hz, 2H), 7.35 (t, J =  
 
8.11 Hz, 1H), 8.53 (br s, 3H). 13C NMR (300 MHz, CD3OD): δ 45.06, 60.44,  
 
61.19, 62.01, 69.12, 70.00, 70.89, 71.37, 73.38, 75.79, 81.13, 94.27, 95.82,  
 
104.07, 155.19, 155.67, 172.02. HRESIMS: Calcd for C17H29N3O10 m/z  
 
435.1853; [M + H]+ m/z 436.1915 (calcd 436.1931).   
 
Preparation of 2-(triphenylmethylthio)ethanamine (8) 
 
Cysteamine hydrochloride (200 mg, 1.73 mmol) was dissolved in 1:1  
 
CH2Cl2:DMF. Trityl chloride (725 mg, 2.60 mmol) was added and the solution  
 
was stirred for 2 h at room temperature. The mixture was then concentrated. The  
 
crude product  was dissolved in CH2Cl2 and washed with satd aq NaHCO3. The  
 
organic phase was dried over MgSO4 and concentrated. The product was purified  
 
by flash chromatography (4:1 CH2Cl2:EtOAc to 4:1 CH2Cl2:MeOH) to yield 416  
 
mg (1.30 mmol, 74%) of 8 as a white solid product. 1H NMR (300 MHz, CDCl3): δ  
 
2.38 (m, 1H), 2.53 (m, 1H), 7.25 (m, 9H), 7.41 (m, 6H). 13C NMR (300 MHz,  
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CDCl3): δ 31.67, 36.73, 126.97, 128.18, 129.78, 144.93. The NMR spectra  
 
matched with those previously reported.17 
 
 




Lactose (223 mg, 0.650 mmol) and 8 (416 mg, 1.30 mmol) were dissolved in a  
 
5% solution of glacial HOAc in DMSO for a saccharide concentration of ~30 mM.  
 
Sodium cyanoborohydride (1.62 g, 26.0 mmol) was added, and the reaction  
 
mixture was heated for 2 h at 65 °C. After dilution with water (15 mL), the mixture  
 
was loaded on reversed phase column, and unreacted saccharide was eluted  
 
with water. Subsequent elution with methanol gave mixture of the product and 8.  
 
The methanol fractions were concentrated and purified by column  
 
chromatography (6:4 CH2Cl2:MeOH to 100% MeOH) to give 327 mg (0.510  
 
mmol, 78%) of 9 as a white solid product.1H NMR (300 MHz, CD3OD): δ 1.90 (br  
 
s, 1H), 2.38-2.71 (m, 6H), 3.34-3.58 (m, 3H), 3.64-3.69 (m, 2H), 3.73-3.87 (m,  
 
6H), 3.96 (m, 1H), 4.42 (d, J = 7.08 Hz, 1H), 7.25 (m, 9H), 7.40 (m, 6H). 13C  
 
NMR (300 MHz, CD3OD): δ 30.47, 51.37, 61.64, 66.85, 66.94, 69.40, 69.81,  
 
71.51, 73.58, 75.92, 77.67, 78.11, 78.54, 80.35, 103.97, 126.79, 127.91, 129.59,  
 
144.86. HRESIMS: Calcd for C33H43NO10S m/z 645.2608; [M + H]+ m/z 646.2713  
 
(calcd 646.2686).   
 
 




Compound 9 (130 mg, 0.202 mmol) was dissolved in a mixture of CH2Cl2 (1 mL)  
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and water (1 mL). Triethylsilane (37 μL, 0.23 mmol) and 3 mL of trifluoroacetic  
 
acid were added, and the two-phase system was vigorously stirred for 40 min,  
 
and then concentrated. The crude material was dissolved in water and purified by  
 
reversed phase chromatography. Elution with water and lyophilization gave 79.1  
 
mg (0.196 mmol, 98%) of 10 as a colorless syrup. 1H NMR (600 MHz, D2O): δ  
 
2.82 (m, 2H), 3.13(dd, J = 10.85 Hz, J = 12.68 Hz, 1H), 3.26 (t, J = 6.87 Hz, 2H),  
 
3.35 (dd, J = 2.98 Hz, J = 12.78 Hz, 1H), 3.49 (dd, J = 7.83 Hz, J = 9.91 Hz, 1H),  
 
3.61 (dd, J = 3.43 Hz, J = 9.97 Hz, 1H), 3.67-3.75 (m, 5H), 3.78 (m, 1H), 3.81- 
 
3.84 (m, 2H), 3.87-3.90 (m, 2H), 4.47 (d, J = 7.82 Hz, 1H). 13C NMR (600 MHz,  
 
D2O): δ 30.62, 46.41, 49.87, 61.61, 61.97, 67.78, 69.29, 71.14, 71.23, 71.55,  
 
73.35, 75.82, 78.57, 103.36. HRDARTMS: Calcd for C14H29NO10S; m/z  
 
403.1512; [M + 6TMS] m/z 836.4091 (calcd 836.4062).   
 
 




1,3-α-D-Mannobiose (25.0 mg, 73.0 μmol) and 8 (47.0 mg, 146 mmol) were  
 
dissolved in a 5% solution of glacial HOAc in DMSO for a saccharide  
 
concentration of ~30 mM. Sodium cyanoborohydride (92.1 g, 1.46 mmol) was  
 
added, and the reaction mixture was heated for 2 h at 65 °C. After dilution with  
 
water (5 mL), the mixture was loaded on a reversed phase column, and  
 
unreacted saccharide was eluted with water. Subsequent elution with methanol  
 
gave mixture of the product and 8. The methanol fractions were concentrated  
 




MeOH) to give 46 mg (71 μmol, 97%) of 11 as a white solid product. 1H NMR  
 
(300 MHz, CD3OD): δ 1.90 (br s, 1H), 2.33-2.90 (m, 6H), 3.48-3.96 (m, 12H),  
 
5.00 (d, J = 1.90 Hz, 1H), 7.41 (m, 6H), 7.29 (m, 9H). 13C NMR (300 MHz,  
 
CD3OD): δ 30.28, 50.79, 61.68, 63.86, 66.86, 67.45, 69.37, 70.81, 70.94, 71.29,  
 
71.50, 74.25, 80.50, 102.60, 126.77, 127.86, 129.56, 144.87. HRESIMS: Calcd  
 
for C33H43NO10S m/z 645.2608; [M + H]+ m/z 646.2642 (calcd 646.2686).   
 
 




Compound 9 (46 mg, 0.071 mmol) was dissolved in a mixture of CH2Cl2 (1 mL)  
 
and water (1 mL). Triethylsilane (30 μL, 0.20 mmol) and 3 mL of trifluoroacetic  
 
acid were added, and the two-phase system was vigorously stirred for 40 min,  
 
and then concentrated. The crude material was dissolved in water and purified by  
 
reversed-phase chromatography. Elution with water and lyophilization gave 27.0  
 
mg (67.0 μmol, 94%) of 12 as a colorless syrup. 1H NMR (600 MHz, D2O): δ 2.83  
 
(m, 2H), 3.18 (dd, J = 10.51 Hz, J = 12.97 Hz, 1H), 3.28 (t, J = 6.43 Hz, 2H), 3.35  
 
(dd, J = 2.82 Hz, J = 12.73 Hz, 1H), 3.50 (dd, J = 7.61 Hz, J = 9.92 Hz, 1H), 3.70- 
 
3.75 (m, 5H), 3.79 (m, 3H), 3.82 (m, 1H), 3.84 (m, 1H), 4.01 (m, 2H), 5.00 (d, J =  
 
1.20 Hz, 1H). 13C NMR (600 MHz, D2O): δ 39.39, 50.21, 50.25, 61.72, 61.93,  
 
63.75, 67.72, 70.74, 70.80, 71.19, 71.47, 74.72, 80.98, 102.80. HRESIMS: Calcd  
 








B. Presentation of Template and Immobilized Clusters on Reactive 
Surfaces 
 
Activation of unfunctionalized slides 
 
Unfunctionalized slides (HTC Super Cured ® Autoclavable) were purchased from  
 
Erie Scientific. The slides were created with a custom mask to produce a 4 x 10  
 
array of spots. NaOH (5 g) was dissolved in 20 mL of ddH2O. EtOH (30 mL) was  
 
added, and the mixture was stirred until dissolution. The solution was poured into  
 
the chamber with slides, and the chamber was covered with glass lid. The slides  
 
were activated for 15 min. The solution was removed, and the slides were  
 
immediately washed vigorously with ddH2O (5 x 30 s) by shaking the  
 
chamber. Aq H2SO4 (5%) was poured into the chamber with the slides to  
 
neutralize any base left on the surfaces. The acidic solution was removed, and  
 
the slides were washed with ddH2O (5 x 30 s) by shaking the chamber. The  
 
slides were kept in ddH2O prior to functionalization. Once the slides were clean,  
 
and rinsed they were exposed to air as little as possible.  
 
Functionalization of glass slides 
 
A 2% solution of aminopropyltrimethoxysilane (APTMS) in 95% EtOH was stirred  
 
for 3 min at room temperature for hydrolysis and silanol formation. The solution  
 
was poured into the chamber with the wet slides. The slides were incubated for 5  
 
min at room temperature and then were briefly washed with abs. EtOH. The  
 
slides were centrifuged to dry and cured under vacuum for 10 min at 110 °C.  
 
 
Reaction of TAMRA with amine-functionalized slides 
 
TAMRA, purchased from AnaSpec, was dissolved in N-methylpyrrolidinone  
 
 136
(NMP, 10 mg/mL) and was diluted to 2 mg/mL with 200 mM disodium phosphate.  
 
The amine-functionalized slides were immediately arrayed with TAMRA solution  
 
(2 μL per well), and the slides were kept in a closed, dark, and humidified  
 
chamber for 1 h. The slides were washed with water, followed by MeOH, and  
 
dried with a stream of nitrogen. Arrays were imaged for TAMRA fluorescence  
 
with a ScanArray 4000XL laser scanner (MicroArray Autoloader, Packard  
 




Maleimide functionalization of glass slides 
 
Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (100 mM,  
 
Pierce, sulfo-SMCC) in NMP was prepared and was diluted to 50 mM with 200  
 
mM disodium phosphate. Prior to derivatization, glass slides were washed briefly  
 
with 1 M HCl, followed by water and then by methanol. The slides were manually  
 
arrayed with sulfo-SMCC (2 μL per well) and were incubated at room  
 
temperature in humidified chambers overnight. The slides were washed briefly  
 
with NMP, followed by MeOH, and dried. Unreacted amines were quenched with  
 
1:4 (v/v) Ac2O in pyridine. After washing with ddH2O and MeOH, the slides were  
 
dried with a stream of nitrogen. 
 
 




2-Mercaptoethylamine (100 mM in ddH2O) was brought to pH 7.5 with 100 mM  
 




well) with the amine and were incubated for 2 h in humidified chamber at room  
 
temperature. The slides were washed with ddH2O, followed by MeOH, and dried  
 
with a stream of nitrogen.  
 
 
Reaction of TAMRA with test ligand 
 
TAMRA was dissolved in NMP (10 mg/mL) and was diluted to 2 mg/mL with 200  
 
mM disodium phosphate solution. The slides with test ligand were immediately  
 
arrayed with TAMRA solution (2 μL per well), and the slides were kept in a  
 
closed, dark, and humidified chamber for 1 h. The slides were washed with  
 
water, followed by MeOH, and then placed on a shaker in NMP for 30 min. The  
 
slides were then briefly washed with MeOH and dried with nitrogen. Arrays were  
 
imaged for TAMRA fluorescence with a ScanArray 4000XL laser scanner  
 
(MicroArray Autoloader, Packard BioChip Technologies) at 85% lockpower and  
 
85% lockgain.  
 
 




A solution of 100 mM of thiol terminated mannose (2 or 12) in ddH2O was  
 
prepared.  Tris(2-carboxyethyl)phosphine (TCEP), 100 mM disodium phosphate  
 
solution and the mannose solution were mixed in a ratio of 0.5:1.5:1 by volume.  
 
TCEP (100 mM in DMF) was used to reduce any disulfide linkages formed. The  
 
slides were arrayed with the mixture and were kept at room temperature in a 
 
humidified chamber for 2 h. The slides were then washed with water, followed by  
 
methanol, and dried with a stream of nitrogen. 
 
 138
Labeling of mannose-binding lectin (MBL) 
 
HBS (10%) was used as buffer and was prepared as follows: 5 g NaCl, 0.2 g of  
 
KCl and 25 mmol of HEPES were dissolved in 80 mL of H2O. The solution was  
 
brought to pH 7.4 with 100 mM NaOH solution and diluted to 100 mL. Mannose- 
 
binding lectin (MBL, 2.6 mg/mL in PBS) was purchased from U.S. Biological.  
 
MBL solution (5 μL) was reacted with 0.5 μL of 100 mM sodium bicarbonate  
 
solution (pH 8.3) and 0.5 μL of TAMRA solution (10 mg/mL in NMP) for 1 h in the  
 
dark. The mixture was filtered to remove unconjugated dye with Millipore  
 
centrifugal filter (regenerated cellulose with 3,000 MWCO, purchased from  
 
Microcon) and washed with 1% HBS. The final concentration of the protein was  
 
found to be 0.60 mg/mL as determined by absorbance spectroscopy (A280: 0.220  
 
nm, A555: 0.390 nm). Labeled MBL to be used was diluted to 0.1 mg/mL with 5  
 
mM CaCl2 in 0.1% BSA in 1% HBS. 
 
 
Visualization with MBL 
 
Slides with mannose ligands were blocked by treatment with HBST (HBS + 1%  
 
Tween 20; 10 min), 3% bovine serum albumin (BSA) in HBST (1–2 h) and HBST  
 
(2 x 15 s). Slides were dried, arrayed with the labeled and diluted MBL and  
 
kept in dark humidified chamber for 2 h. Unbound protein was washed briefly  
 
with 5 mM CaCl2 in 0.1 % BSA in HBST and centrifuged. Arrays were imaged for  
 
TAMRA-MBL fluorescence with a ScanArray 4000XL laser scanner (MicroArray  
 
Autoloader, Packard BioChip Technologies) with 90% lockpower and  
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1H NMR spectrum (300 MHz, CDCl3) of 2-hydroxy-2-(4,7,12-trioxo-7,12-dihydro-4H-naphtho[2,3-h]chromen-













13C NMR spectrum (300 MHz, CDCl3) of 2-hydroxy-2-(4,7,12-trioxo-7,12-dihydro-4H-naphtho[2,3-h]chromen-













1H NMR spectrum (300 MHz, CDCl3) of 2-hydroxy-2-(oxiran-2-yl)-2-(4,7,12-trioxo-7,12-dihydro-4H-














13C NMR spectrum (300 MHz, CDCl3) of 2-hydroxy-2-(oxiran-2-yl)-2-(4,7,12-trioxo-7,12-dihydro-4H-naphtho[2,3-














1H NMR spectrum (300 MHz, CDCl3) of 2-hydroxy-2-(oxiran-2-yl)-2-(4,7,12-trioxo-7,12-dihydro-4H-naphtho[2,3-














13C NMR spectrum (300 MHz, CDCl3) of 2-hydroxy-2-(oxiran-2-yl)-2-(4,7,12-trioxo-7,12-dihydro-4H-naphtho[2,3-
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